CA2559700C - Benzoxazine for treating respiratory tract diseases - Google Patents
Benzoxazine for treating respiratory tract diseases Download PDFInfo
- Publication number
- CA2559700C CA2559700C CA2559700A CA2559700A CA2559700C CA 2559700 C CA2559700 C CA 2559700C CA 2559700 A CA2559700 A CA 2559700A CA 2559700 A CA2559700 A CA 2559700A CA 2559700 C CA2559700 C CA 2559700C
- Authority
- CA
- Canada
- Prior art keywords
- denotes
- compound
- formula
- acid addition
- addition salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000018569 Respiratory Tract disease Diseases 0.000 title abstract description 3
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 111
- 229910052739 hydrogen Inorganic materials 0.000 claims description 53
- 239000001257 hydrogen Substances 0.000 claims description 53
- 239000002253 acid Substances 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 41
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 39
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 37
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 37
- 239000000460 chlorine Substances 0.000 claims description 37
- 229910052801 chlorine Inorganic materials 0.000 claims description 37
- 239000011737 fluorine Substances 0.000 claims description 37
- 229910052731 fluorine Inorganic materials 0.000 claims description 37
- -1 methoxy, ethoxy Chemical group 0.000 claims description 29
- 150000002431 hydrogen Chemical class 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- 208000006673 asthma Diseases 0.000 claims description 15
- 206010006451 bronchitis Diseases 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 8
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 8
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 208000019693 Lung disease Diseases 0.000 claims description 7
- 206010035664 Pneumonia Diseases 0.000 claims description 7
- 208000030934 Restrictive pulmonary disease Diseases 0.000 claims description 7
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 6
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 230000000241 respiratory effect Effects 0.000 claims description 5
- 206010014561 Emphysema Diseases 0.000 claims description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 208000011623 Obstructive Lung disease Diseases 0.000 claims description 4
- 206010035742 Pneumonitis Diseases 0.000 claims description 4
- 201000009267 bronchiectasis Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- 206010052613 Allergic bronchitis Diseases 0.000 claims description 2
- 206010001889 Alveolitis Diseases 0.000 claims description 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims description 2
- 206010053132 Lymphangiosis carcinomatosa Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 201000010001 Silicosis Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 208000024716 acute asthma Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 206010003441 asbestosis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 244000000013 helminth Species 0.000 claims description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 230000001473 noxious effect Effects 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 239000003440 toxic substance Substances 0.000 claims description 2
- 230000001960 triggered effect Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 12
- COUYJEVMBVSIHV-UHFFFAOYSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-UHFFFAOYSA-N 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 79
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 72
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 46
- 238000000034 method Methods 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 41
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 239000007787 solid Substances 0.000 description 33
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000013543 active substance Substances 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
- 239000002904 solvent Substances 0.000 description 26
- 238000004949 mass spectrometry Methods 0.000 description 21
- 238000000926 separation method Methods 0.000 description 21
- 235000011167 hydrochloric acid Nutrition 0.000 description 19
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 239000003054 catalyst Substances 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000000843 powder Substances 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 11
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- 229960001375 lactose Drugs 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000003380 propellant Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- XEKAWZARUWARND-UHFFFAOYSA-N 6h-oxazin-3-one Chemical compound O=C1NOCC=C1 XEKAWZARUWARND-UHFFFAOYSA-N 0.000 description 5
- ASAUWRRCICGVSS-UHFFFAOYSA-N 8-(2-ethoxy-2-hydroxyacetyl)-2-phenylmethoxy-4h-1,4-benzoxazin-3-one Chemical compound O1C=2C(C(=O)C(O)OCC)=CC=CC=2NC(=O)C1OCC1=CC=CC=C1 ASAUWRRCICGVSS-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 5
- 238000006434 Ritter amidation reaction Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000000808 adrenergic beta-agonist Substances 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229940037001 sodium edetate Drugs 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 235000011149 sulphuric acid Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- LPHDEWSUQKMYMG-UHFFFAOYSA-N 8-(2-ethoxy-2-hydroxyacetyl)-6-phenylmethoxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C=2NC(=O)COC=2C(C(=O)C(O)OCC)=CC=1OCC1=CC=CC=C1 LPHDEWSUQKMYMG-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000003454 betamimetic effect Effects 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000007327 hydrogenolysis reaction Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- NFMPBJPUTVLPDD-UHFFFAOYSA-N oxaldehyde;6-phenylmethoxy-4h-1,4-benzoxazin-3-one;hydrate Chemical compound O.O=CC=O.C1=C2NC(=O)COC2=CC=C1OCC1=CC=CC=C1 NFMPBJPUTVLPDD-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000001117 sulphuric acid Substances 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000008139 complexing agent Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 238000006264 debenzylation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QIDZFEAYVSWPIH-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)-2-methylpropan-2-amine Chemical compound CC(C)(N)CC1=CC=C(F)C=C1Cl QIDZFEAYVSWPIH-UHFFFAOYSA-N 0.000 description 2
- KXDPFNVAEQJUIT-UHFFFAOYSA-N 1-(4-ethoxyphenyl)-2-methylpropan-2-amine Chemical compound CCOC1=CC=C(CC(C)(C)N)C=C1 KXDPFNVAEQJUIT-UHFFFAOYSA-N 0.000 description 2
- LXWXXYJYGJKFOI-UHFFFAOYSA-N 1-(4-ethylphenyl)-2-methylpropan-2-amine Chemical compound CCC1=CC=C(CC(C)(C)N)C=C1 LXWXXYJYGJKFOI-UHFFFAOYSA-N 0.000 description 2
- FDKVQXHBNNQCNP-UHFFFAOYSA-N 1-(4-fluoro-2-methylphenyl)-2-methylpropan-2-amine Chemical compound CC1=CC(F)=CC=C1CC(C)(C)N FDKVQXHBNNQCNP-UHFFFAOYSA-N 0.000 description 2
- CPNNQIURQAQQSU-UHFFFAOYSA-N 2-methyl-1-(4-propan-2-ylphenyl)propan-2-amine Chemical compound CC(C)C1=CC=C(CC(C)(C)N)C=C1 CPNNQIURQAQQSU-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- MYELJUJVRZVIOC-UHFFFAOYSA-N 8-(2,2-dihydroxyacetyl)-6-phenylmethoxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C=2NC(=O)COC=2C(C(=O)C(O)O)=CC=1OCC1=CC=CC=C1 MYELJUJVRZVIOC-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 239000005711 Benzoic acid Chemical class 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- VMQBFYRBJKDACN-UHFFFAOYSA-N HBOA Chemical compound C1=CC=C2NC(=O)C(O)OC2=C1 VMQBFYRBJKDACN-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- WNULYKWIGSZELF-UHFFFAOYSA-N benzyl n-[1-(4-hydroxyphenyl)-2-methylpropan-2-yl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(C)(C)CC1=CC=C(O)C=C1 WNULYKWIGSZELF-UHFFFAOYSA-N 0.000 description 2
- 125000001743 benzylic group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 238000004508 fractional distillation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000005635 hydromethanesulphonate group Chemical group 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZAWIHARPILBRQM-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-2-methylpropan-2-amine Chemical compound CC(C)(N)CC1=CC=C(F)C=C1F ZAWIHARPILBRQM-UHFFFAOYSA-N 0.000 description 1
- XUOSNNGPUHIOIK-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-2-methylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=C(F)C=C1F XUOSNNGPUHIOIK-UHFFFAOYSA-N 0.000 description 1
- QRTNRWGXBWSNHN-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)-2-methylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=C(F)C=C1Cl QRTNRWGXBWSNHN-UHFFFAOYSA-N 0.000 description 1
- QLPLPEPHQBKUOA-UHFFFAOYSA-N 1-(3,4-difluorophenyl)-2-methylpropan-2-amine Chemical compound CC(C)(N)CC1=CC=C(F)C(F)=C1 QLPLPEPHQBKUOA-UHFFFAOYSA-N 0.000 description 1
- ZHJNDDKGFIIIST-UHFFFAOYSA-N 1-(3,4-difluorophenyl)-2-methylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=C(F)C(F)=C1 ZHJNDDKGFIIIST-UHFFFAOYSA-N 0.000 description 1
- YYESFPVLOJOMPC-UHFFFAOYSA-N 1-(3,5-difluorophenyl)-2-methylpropan-2-ol Chemical compound CC(C)(O)CC1=CC(F)=CC(F)=C1 YYESFPVLOJOMPC-UHFFFAOYSA-N 0.000 description 1
- BRHJQGXNUNEFSA-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-2-methylpropan-2-amine Chemical compound CC1=CC(C)=CC(CC(C)(C)N)=C1 BRHJQGXNUNEFSA-UHFFFAOYSA-N 0.000 description 1
- DNAGWILBAXAZOH-UHFFFAOYSA-N 1-(4-ethylphenyl)propan-2-one Chemical compound CCC1=CC=C(CC(C)=O)C=C1 DNAGWILBAXAZOH-UHFFFAOYSA-N 0.000 description 1
- PXYGISCPEJXQLN-UHFFFAOYSA-N 1-(4-fluoro-3-methylphenyl)-2-methylpropan-2-amine Chemical compound CC1=CC(CC(C)(C)N)=CC=C1F PXYGISCPEJXQLN-UHFFFAOYSA-N 0.000 description 1
- JITFIYFVPMQJOK-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-methylpropan-2-amine Chemical compound CC(C)(N)CC1=CC=C(F)C=C1 JITFIYFVPMQJOK-UHFFFAOYSA-N 0.000 description 1
- KVSVNRFSKRFPIL-UHFFFAOYSA-N 1-(bromomethyl)-3,5-difluorobenzene Chemical compound FC1=CC(F)=CC(CBr)=C1 KVSVNRFSKRFPIL-UHFFFAOYSA-N 0.000 description 1
- CYAKWEQUWJAHLW-UHFFFAOYSA-N 1-(chloromethyl)-4-propan-2-ylbenzene Chemical compound CC(C)C1=CC=C(CCl)C=C1 CYAKWEQUWJAHLW-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HKOJYPPTIPJZAZ-UHFFFAOYSA-N 2-methoxy-6-methylaniline Chemical compound COC1=CC=CC(C)=C1N HKOJYPPTIPJZAZ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JJIFTOPVKWDHJI-UHFFFAOYSA-N 4-(bromomethyl)-1,2-difluorobenzene Chemical compound FC1=CC=C(CBr)C=C1F JJIFTOPVKWDHJI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- DUPOKJDATDIUGO-UHFFFAOYSA-N 8-[2-[[1-(2-chloro-4-fluorophenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(F)C=C1Cl DUPOKJDATDIUGO-UHFFFAOYSA-N 0.000 description 1
- LLQJQYIOQUUNMV-UHFFFAOYSA-N 8-[2-[[1-(4-ethylphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(CC)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 LLQJQYIOQUUNMV-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical class C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical class C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical class CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- SWSQUPDDGGYHLR-UHFFFAOYSA-M [Br-].CC1=CC(F)=CC=C1[Mg+] Chemical compound [Br-].CC1=CC(F)=CC=C1[Mg+] SWSQUPDDGGYHLR-UHFFFAOYSA-M 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001273 butane Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 108010062049 chirobiotic T Proteins 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- ZGLFZLKBBSUQPS-UHFFFAOYSA-N ethyl 2-(3,5-dimethylphenyl)acetate Chemical compound CCOC(=O)CC1=CC(C)=CC(C)=C1 ZGLFZLKBBSUQPS-UHFFFAOYSA-N 0.000 description 1
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 244000243234 giant cane Species 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- DFTYYBRLWCAUHP-UHFFFAOYSA-N methyl 2-(2-chloro-4-fluorophenyl)acetate Chemical compound COC(=O)CC1=CC=C(F)C=C1Cl DFTYYBRLWCAUHP-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- WSTMHCWBUXFLDO-UHFFFAOYSA-N n-[1-(2-chloro-4-fluorophenyl)-2-methylpropan-2-yl]formamide Chemical compound O=CNC(C)(C)CC1=CC=C(F)C=C1Cl WSTMHCWBUXFLDO-UHFFFAOYSA-N 0.000 description 1
- SNXQFTKJDUXKEH-UHFFFAOYSA-N n-[1-(4-fluoro-3-methylphenyl)-2-methylpropan-2-yl]formamide Chemical compound CC1=CC(CC(C)(C)NC=O)=CC=C1F SNXQFTKJDUXKEH-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Chemical class CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000001294 propane Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The invention relates to the use of compounds of general formula (1), wherein the radicals R1, R2 and R3 can have the meaning cited in the claims and in the description. The invention also relates to the production of a medicament for treating respiratory tract diseases.
Description
BENZOXAZINE FOR TREATING RESPIRATORY TRACT DISEASES
The present invention relates to the use of the compounds of general formula 1 OH
Me Me HN n ISR 1 R3 OH
wherein the groups R1, R2 and R3 may have the meanings given herein, for preparing a pharmaceutical composition for the treatment of respiratory complaints.
Background to the invention --Betamimetics (13-adrenergic substances) are known from the prior art. For example reference may be made in this respect to the disclosure of US 4,460,581, which proposes betamimetics for the treatment of a range of diseases.
For drug treatment of diseases it is often desirable to prepare medicaments with a longer duration of activity. As a rule, this ensures that the concentration of the active substance in the body needed to achieve the therapeutic effect is guaranteed for a longer period without the need to re-administer the drug at frequent intervals. Moreover, giving an active substance at longer time intervals contributes to the well-being of the patient to a high degree. It is particularly desirable to prepare a pharmaceutical composition which can be used therapeutically by administration once a day (single dose). The use of a drug once a day has the advantage that the patient can become accustomed relatively quickly to regularly taking the drug at certain times of the day.
The aim of the present invention is therefore to provide betamimetics which on the one hand confer a therapeutic benefit in the treatment of respiratory complaints and are also characterised by a longer duration of activity and can thus be used to prepare pharmaceutical compositions with a longer duration of activity. A particular aim of the invention is to prepare betamimetics which, by virtue of their long-lasting effect, can be used to prepare a drug for administration once a day for treating asthma. A
further objective of the invention, apart from those mentioned above, is to prepare new betamimetics which are not only exceptionally potent but are also characterised by a high degree of selectivity with respect to the 13-adrenoceptor.
Detailed description of the invention It has been found that, surprisingly, the above-mentioned problems are solved by compounds of general formula 1.
Accordingly, the present invention relates to the use of one or more, preferably one, compound of general formula 1 OH
Me Me R
wherein denotes 1 or 2, preferably 1;
RI denotes hydrogen, halogen, CI-C4-alkyl or -0-C1-C4-alkyl;
R2 denotes hydrogen, halogen, Ci-C4-alkyl or -0-C1-C4-alkyl;
R3 denotes CI-C4-alkyl, OH, halogen, -0-Ci-C4-alkyl, -0-Ci-C4-alkylene-COOH, -0-Ci-C4-alkylene-00-0-CI-C4-alkyl, with the proviso that if Ri and R2 each denote ortho-methyl, R3 cannot simultaneously be OH, for preparing a pharmaceutical composition for the treatment of respiratory complaints selected from the group comprising obstructive pulmonary diseases of various origins, pulmonary emphysema of various origins, restrictive pulmonary diseases, interstitial pulmonary diseases, cystic fibrosis, bronchitis of various origins, bronchiectasis, ARDS (adult respiratory distress syndrome) and all forms of pulmonary oedema.
Preferably, the compounds of general formula 1 used as specified above are those wherein denotes 1 or 2, preferably 1;
RI denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R2 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R3 denotes Ci-C4-alkyl, OH, fluorine, chlorine, bromine, -0-C1-C4-alkyl, -0-C1-C4-alkylene-COOH, -0-C1-C4-alkylene-00-0-Ci-C4-alkyl, with the proviso that if RI and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
Preferably, the compounds of general formula 1 used as specified above are those wherein denotes 1;
RI denotes hydrogen or Ci-C4-alkyl;
R2 denotes hydrogen or CI-C4-alkyl;
R3 denotes Ci-C4-alkyl, OH, -0-C1-C4-alkyl, -0-C1-C4-alkylene-COOH or -0-C1-C4- alkylene-00-0-Ci-C4-alkyl, with the proviso that if RI and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
Preferably, the compounds of general formula 1 used as specified above are those wherein n denotes 1;
RI denotes hydrogen, methyl or ethyl;
R2 denotes hydrogen, methyl or ethyl;
R3 denotes methyl, ethyl, OH, methoxy, ethoxy, -0-CH2-COOH, -0-CH2-COOmethyl or -0-CH2-COOethyl, with the proviso that if RI and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
Preferably, the compounds of general formula 1 used as specified above are those wherein denotes 1;
RI denotes hydrogen or methyl;
R2 denotes hydrogen or methyl;
R3 denotes methyl, OH, methoxy, -0-CH2-COOH or -0-CH2-COOethyl, with the proviso that if RI and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
Preferably, according to the invention, the compounds of general formula 1 used as specified above are those wherein R3 denotes methoxy, ethoxy, -0-CH2-COOH, -0-CH2-COOmethyl or -0-CH2-COOethyl, and RI, R2 and n may have the meanings given above.
The present invention further relates to the above-mentioned use of compounds of general formula 1 wherein n denotes 1;
RI denotes halogen, Ci-C4-alkyl or -0-C i-C4-alkyl;
R2 denotes halogen, Ci-C4-alkyl or -0-Ci-C4-alkyl;
R3 denotes halogen, CI-C4-alkyl or -0-Ci-C4-alkyl.
The present invention further relates to the above-mentioned use of compounds of general formula 1 wherein denotes 1;
RI denotes fluorine, chlorine, methyl or methoxy;
R2 denotes fluorine, chlorine, methyl or methoxy;
R3 denotes fluorine, chlorine, methyl or methoxy.
According to another preferred aspect of the present invention the compounds of general formula 1 used as specified above are those wherein n denotesl;
RI denotes hydrogen;
R2 denotes hydrogen, fluorine, chlorine or methyl;
R3 denotes methyl, ethyl, iso-propyl, tert.-butyl, OH, fluorine, chlorine, bromine, methoxy, ethoxy, -0-CH2-COOH, -0-CH2-CH2-COOH, -0-CH2-CH2-CH2-COOH, -0-CH2-COOmethyl, -0-CH2-COOethyl, -0-CH2-CH2-COOmethyl, -0-CH2-CH2-COOethyl, -0-CH2-CH2-CH2-COOmethyl or -0-CH2-CH2-CH2-COOethyl.
Particularly preferably, the compounds of general formula! used as specified above are those wherein denotes 1;
R1 denotes hydrogen;
R2 denotes hydrogen, fluorine, chlorine or methyl;
R3 denotes OH, fluorine, chlorine, methyl, methoxy, ethoxy or -0-CH2-COOH.
Moreover it is particularly preferable according to the invention if the compounds of general formula 1 according to the invention used as specified above are those wherein denotes 1;
RI denotes hydrogen;
R2 denotes halogen, CI-C4-alkyl or -0-C1-C4-alkyl, preferably fluorine, chlorine, methoxy or methyl;
R3 denotes halogen, CI-C4-alkyl or -0-C1-C4-alkyl, preferably fluorine, chlorine, methoxy or methyl.
In another preferred aspect of the present invention the compounds of general formula 1 according to the invention used as specified above are those wherein n = 1 , RI and R2 denote hydrogen and the group R3 may have the meanings given above.
In another preferred aspect of the present invention the compounds of general formula 1 according to the invention used as specified above are those wherein RI and R2 denote hydrogen;
R3 denotes methyl, ethyl, iso-propyl, tert.-butyl, OH, fluorine, chlorine, bromine, methoxy, ethoxy, -0-CH2-COOH, -0-CH2-CH2-COOH, -0-CH2-CH2-CH2-COOH, -0-CH2-COOmethyl, -0-CH2-COOethyl, -0-CH2-CH2-COOmethyl, -0-CH2-CH2-COOethyl, -0-CH2-CH2-CH2-COOmethyl, -0-CH2-CH2-CH2-COOethyl.
Particularly preferably the compounds of general formula 1 according to the invention used as specified above are those wherein n denotes 1;
RI and R2 denote hydrogen;
R3 denotes OH, fluorine, chlorine, methoxy, ethoxy,-0-CH2-COOH, preferably OH, fluorine, chlorine, ethoxy or methoxy.
Particularly preferably the compounds of general formula 1 according to the invention used as specified above are those wherein denotes 1;
RI and R2 denote hydrogen;
R3 denote fluorine, chlorine, methoxy or ethoxy.
The present invention further relates to the above-mentioned use of compounds of general formula 1, wherein denotes 1;
Ri denotes hydrogen, halogen, Ci-C4-alkyl or -0-C i-C4-alkyl;
R2 denotes hydrogen, halogen, Ci-C4-alkyl or -0-C1-C4-alkyl;
R3 denotes hydrogen.
Preferably, the compounds of general formula! used as specified above are those wherein n denotes 1;
RI denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R2 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R3 denotes hydrogen.
The present invention further relates to the above-mentioned use of compounds of general formula 1, wherein denotes 1;
RI denotes fluorine, chlorine, methyl or methoxy;
R2 denotes fluorine, chlorine, methyl or methoxy;
R3 denotes hydrogen.
In the compounds of formula! the groups RI and R2, if they do not represent hydrogen, may each be arranged in the ortho or meta position relative to the bond to the benzylic "-CH2" group. If none of the groups RI and R2 denotes hydrogen, preferred compounds of formula! for the use according to the invention are those wherein either both groups RI
and R2 are ortho or both groups RI and R2 are in the meta configuration, while compounds in which both groups RI and R2 are in the ortho-configuration are of particular importance.
In the compounds of formula! wherein one of the groups RI and R2 does not denote hydrogen, this group may be in the ortho or meta position relative to the bond to the benzylic "-CH2" group. In this case those compounds of formula! wherein the group RI or R2 which does not denote hydrogen is in the ortho configuration are particularly preferred for use according to the invention.
Particularly preferably, one or more of the following compounds of general formula! are used for the purpose described above:
- 6-hydroxy-8-{1-hydroxy-242-(4-methoxy-pheny1)-1,1-dimethyl-ethylaminol-ethyll-4H-benzo[1,4]oxazin-3-one;
- 6-hydroxy-8- {1-hydroxy-2-[2-(4- ethyl-phenoxy-acetate)-1,1-dimethyl-ethylamino]-ethy1}-4H-benzo[1,4]oxazin-3-one;
- 6-hydroxy-8- {1-hydroxy-2-[2-(4-phenoxy-acetic acid)-1,1-dimethyl-ethylamino]-ethy1}-4H-benzo[1,4]oxazin-3-one;
- 8- {2-[1,1-dimethy1-2-(2,4,6-trimethylpheny1)-ethylamino]-1-hydroxy-ethyll-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 6-hydroxy-8- {1-hydroxy-242-(4-hydroxy-pheny1)-1,1-dimethyl-ethylaminoFethyl} -4H-benzo[1,4]oxazin-3-one;
- 6-hydroxy-8- {1-hydroxy-242-(4-isopropyl-pheny1)-1,1dimethyl-ethylamino}-ethyll -4H-benzo[1,4]oxazin-3-one;
- 8- {212-(4-ethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzorl ,4]oxazin-3-one;
- 8- {242-(4-fluoro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo [1,4]oxazin-3-one;
- 8- {212-(4-fluoro-2-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-hydroxy-4H-benzo[1,41oxazin-3-one;
- 8- {242-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(4-ethoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo [1,4]oxazin-3-one;
- 4-(4- {242-hydroxy-2-(6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-ethylamino]-2-methyl-propyll-phenoxy)-butyric acid;
- 8- {24243 ,4-di fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(2-chloro-4-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4]oxazin-3-one;
- 8- {242-(4-chloro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(4-bromo-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(4-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8-1242-(4-fluoro-3-methoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(4-fluoro-2,6-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[l ,4]oxazin-3-one;
- 8- {242-(4-chloro-2-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {212-(4-chloro-3-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-. hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(4-chloro-2-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4] oxazin-3-one;
- 8- {2-[2-(3-chloro-4-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(2,6-difluoro-4-methoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8-1242-(2,5-difluoro-4-methoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo [1,4] oxazin-3-one;
- 8- {242-(4-fluoro-3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(3,5-dichloro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {2-[2-(4-chloro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {2-[2-(3,4,5-trifluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one and - 8- (242-(3,4-dichloro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one.
A particularly preferred compound is 6-hydroxy-8-11-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl)-4H-benzo[1,4]oxazin-3-one. The R-enantiomer of the compound is specifically preferred.
In another aspect the present invention relates to the above-mentioned use of the compounds of formula 1 in the form of the individual optical isomers, or mixtures of the individual enantiomers or racemates. It is particularly preferable to use the compounds of formula! for the purpose described above in the form of the enantiomerically pure compounds, while the use of the R-enantiomers of the compounds of formula 1 is of exceptional importance according to the invention.
In another aspect the present invention relates to the above-mentioned use of the compounds of formula! in the form of the acid addition salts with pharmacologically acceptable acids as well as optionally in the form of the solvates and/or hydrates.
The compounds of general formula! are preferably used for preparing a pharmaceutical composition for the treatment of obstructive pulmonary diseases selected from among bronchial asthma, paediatric asthma, severe asthma, acute asthma attacks and chronic bronchitis, while it is particularly preferable according to the invention to use them for preparing a pharmaceutical composition for the treatment of bronchial asthma.
It is also preferable to use the compounds of general formula! for preparing a pharmaceutical composition for the treatment of pulmonary emphysema which has its origins in COPD (chronic obstructive pulmonary disease) or al -proteinase inhibitor deficiency.
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of restrictive pulmonary diseases selected from among allergic alveolitis, restrictive pulmonary diseases triggered by work-related noxious substances, such as asbestosis or silicosis, and restriction caused by lung tumours, such as for example lymphangiosis carcinomatosa, bronchoalveolar carcinoma and lymphomas.
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of interstitial pulmonary diseases selected from among pneumonia caused by infections, such as for example infection by viruses, bacteria, fungi, protozoa, helminths or other pathogens, pneumonitis caused by various factors, such as for example aspiration and left heart insufficiency, radiation-induced pneumonitis or fibrosis, collagenoses, such as for example lupus erythematodes, systemic sclerodermy or sarcoidosis, granulomatoses, such as for example Boeck's disease, idiopathic interstitial pneumonia or idiopathic pulmonary fibrosis (IPF).
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of cystic fibrosis or mucoviscidosis.
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of bronchitis, such as for example bronchitis caused by bacterial or viral infection, allergic bronchitis and toxic bronchitis.
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of bronchiectasis.
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of ARDS (adult respiratory distress syndrome).
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of pulmonary oedema, for example toxic pulmonary oedema after aspiration or inhalation of toxic substances and foreign substances.
It is particularly preferable to use the compounds detailed above for preparing a pharmaceutical composition for the treatment of asthma or COPD. Also of particular importance is the above-mentioned use of compounds of formula 1 for preparing a pharmaceutical composition for once-a-day treatment of inflammatory and obstructive respiratory complaints, particularly for the once-a-day treatment of asthma.
The present invention also relates to a process for the treatment of the above-mentioned diseases, characterised in that one or more of the above-mentioned compounds of general formula 1 are administered in therapeutically effective amounts. The present invention further relates to processes for the treatment of Asthma, characterised in that one or more of the above-mentioned compounds of general formula 1 are administered once a day in therapeutically effective amounts.
By acid addition salts with pharmacologically acceptable acids are meant for example salts selected from the group comprising the hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate, preferably the hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate.
Of the above-mentioned acid addition salts, the salts of hydrochloric acid, methanesulphonic acid, benzoic acid and acetic acid are particularly preferred according to the invention.
For use according to the invention the compounds of general formula! may optionally be used in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates. If the compounds are used in enantiomerically pure form, the R-enantiomers are preferably used.
Unless otherwise stated, the alkyl groups are straight-chained or branched alkyl groups having Ito 4 carbon atoms. The following are mentioned by way of example:
methyl, ethyl, propyl or butyl. In some cases the abbreviations Me, Et, Prop or Bu are used to denote the groups methyl, ethyl, propyl or butyl. Unless otherwise stated, the definitions propyl and butyl include all the possible isomeric forms of the groups in question. Thus, for example, propyl includes n-propyl and iso-propyl, butyl includes iso-butyl, sec.butyl and tert.-butyl, etc.
Unless otherwise stated, the alkylene groups are branched and unbranched double-bonded alkyl bridges having 1 to 4 carbon atoms. The following are mentioned by way of example: methylene, ethylene, n-propylene or n-butylene.
Unless otherwise stated, the term alkyloxy groups (or -0-alkyl groups) denotes branched and unbranched alkyl groups having 1 to 4 carbon atoms which are linked via an oxygen atom. Examples of these include: methyloxy, ethyloxy, propyloxy or butyloxy.
The abbreviations Me0-, Et0-, Prop0- or BuO- are used in some cases to denote the groups methyloxy, ethyloxy, propyloxy or butyloxy. Unless otherwise stated, the definitions propyloxy and butyloxy include all possible isomeric forms of the groups in question.
Thus, for example, propyloxy includes n-propyloxy and iso-propyloxy, butyloxy includes iso-butyloxy, sec.butyloxy and tert.-butyloxy, etc. In some cases, within the scope of the present invention, the term alkoxy is used instead of the term alkyloxy.
Accordingly, the terms methoxy, ethoxy, propoxy or butoxy may also be used to denote the groups methyloxy, ethyloxy, propyloxy or butyloxy.
halogen within the scope of the present invention denotes fluorine, chlorine, bromine or iodine. Unless stated otherwise, fluorine, chlorine and bromine are the preferred halogens.
The compounds according to the invention may be prepared analogously to methods already known from the prior art. Suitable methods of preparation are known for example from US 4460581, to the entire contents of which reference is made at this point.
The examples of synthesis described below serve to illustrate new compounds according to the invention in more detail. However, they are intended only as examples of procedures to illustrate the invention without restricting it to the subject matter described in an exemplifying capacity hereinafter.
Example 1: 6-hydroxy-8- 1L1-hydroxy-242-(4-methoxy-pheny1)-1,1-dimethyl-ethylamino1-ethyll-4H-benzo[1,4]oxazin-3-one o OH
HN
Me Me OMe OH
a) 8-{241,1-dimethy1-2-(4-methoxy-pheny1)-ethylamino}-1-hydroxy-ethyll-6-benzyloxy-4H-benzo[1,4]oxazin-3-one 7.5 g (6-benzyloxy-4H-benzo[1,4]oxazin-3-one)-glyoxalhydrate are added at 70 C
to a solution of 3.6 g 1,1-dimethy1-2-(4-methoxypheny1)-ethylamine in 100 mL
ethanol and the mixture is stirred for 15 minutes. Then within 30 minutes at 10 to 20 C 1 g sodium borohydride is added. The mixture is stirred for one hour, combined with 10 mL
acetone and stirred for a further 30 minutes. The reaction mixture is diluted with 150 mL ethyl acetate, washed with water, dried with sodium sulphate and evaporated down.
The residue is dissolved in 50 mL methanol and 100 mL ethyl acetate and acidified with conc.
hydrochloric acid. After the addition of 100 mL diethyl ether the product is precipitated out. The crystals are filtered off, washed and recrystallised from 50 mL
ethanol.
Yield: 7 g (68%; hydrochloride); m.p. = 232-234 C.
b) 8- {241,1-dimethy1-2-(4-methoxy-pheny1)-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one 6.8 g of the benzyl compound obtained previously are hydrogenated in 125 mL
methanol with the addition of 1 g palladium on charcoal (5%) at ambient temperature and normal pressure. The catalyst is filtered off and the filtrate is freed from solvent.
After recrystallisation of the residue from 50 mL acetone and some water a solid is obtained which is filtered off and washed.
Yield: 5.0 g (89 %; hydrochloride); m.p. = 155-160 C.
The (R)- and (S)-enantiomers of Example 1 may be obtained from the racemate, for example, by means of chiral HPLC (e.g. column: Chirobiotic T, 250 x 22.1 mm supplied by Messrs Astec). The mobile phase used may be methanol with 0.05 %
triethylamine and 0.05% acetic acid. Silica gel with a particle size of 5 p,m, to which the glycoprotein teicoplanin is covalently bound, may be used as column material.
Retention time (R-enantiomer) = 40.1 min, retention time (S-enantiomer) = 45.9 min. The two enantiomers are obtained by this method in the form of the free bases.
Of outstanding importance according to the invention is the R-enantiomer of Example 1.
Example 2: 6-h_ydroxy-8-{1-hydroxy-242-( ethyl 4-phenoxy-acetate)-1,1-dimethyl-ethylaminoi-ethyll-4H-benzo[1,4]oxazin-3-one HN OH
OH Me Me 1. 0- y 0 ,OEthyl a) 8- {211,1-dimethy1-24 ethyl 4-phenoxy-acetate)-ethylamino]-1-hydroxy-ethy11-benzyloxy-4H-benzo[1,4]oxazin-3-one Analogously to the method described in Example la) the title compound is obtained from g (6-benzyloxy-4H-benzo[1,4]oxazin-3-one)-glyoxalhydrate and 11.8 g 1,1-dimethy1-2-( ethyl 4-phenoxy-acetate)-ethylamine hydrochloride.
15 Yield: 16.5 g (69%, hydrochloride); m.p. = 212-214 C.
b) 8- {2-11,1-dimethy1-2-(4-phenoxy-acetate ethyl)-ethylamino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,4Joxazin-3-one 8 g of the benzylalcohol obtained previously are dissolved in 100 mL ethanol, 100 mL
methanol and 10 mL water and hydrogenated in the presence of 1 g palladium on charcoal (5%). After uptake of the theoretical amount of hydrogen calculated the catalyst is filtered off and the filtrate is evaporated down. The product that crystallises out when the solvent is distilled off is suction filtered and washed.
Yield: 5.5 g (81%; hydrochloride); m.p. = 137-140 C.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
, Example 3: 6-hydroxy-8- { I -hydroxy-2-[2-(4-phenoxy-acetic acid)-1,1-dimethyl-ethylaminoFethyl } -4H-benzo[1,4]oxazin-3-one C)0 OH H
HN I. N
Me Me 11101 0-.COOH
OH
11 g 8-{2-[1,1-dimethy1-2-(4-phenoxy-acetate ethyl)-ethylamino]-1-hydroxy-ethyl} -6-benzyloxy-4H-benzo[1,4]oxazin-3-one hydrochloride (Example 4a) are dissolved in 125 mL methanol and hydrogenated in the presence of 1 g palladium on charcoal (5%). After uptake of the theoretically calculated amount of hydrogen the catalyst is filtered off 2.6 g sodium hydroxide dissolved in 20 mL water are added to the filtrate. The mixture is refluxed for 30 minutes, the methanol is distilled off and the residue is combined with 10 mL water, 20 mL n-butanol and 3.9 mL acetic acid. The precipitated solid is suction filtered and washed with diethyl ether.
Yield: 7 g (87%). The hydrochloride is obtained by recrystallisation from 0.5 molar hydrochloric acid. M.p. = 152 C.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 4: 8- {2-11,1-dimethy1-2-(2,4,6-trimethylpheny1)-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one C)0 OH H Me Me Me 0 Me Me OH
a) 1-(6-benzyloxy-4H-benzo[1,4]oxazin-3-one)-211,1-dimethy1-2-(2,4,6-trimethylpheny1)-ethyliminoi-ethanone 7.2 g (6-benzyloxy-4H-benzo[1,4]oxazin-3-one)-glyoxalhydrate and 3.6 g 1,1-dimethy1-2-(2,4,6-trimethylpheny1)-ethylamine are heated to 70 C for one hour in 100 mL
ethanol.
, WO 2005/102350 CA 02559700 2006-09-After cooling the solid precipitated is filtered off and washed with ethanol and diethyl ether. Yield: 8.6 g (94%); m.p. = 175 C.
b) 8- {2-[1,1-dimethy1-2-(2,4,6-trimethylpheny1)-ethylamino]-1-hydroxy-ethyll-benzylox_y-4H-benzo[1,4]oxazin-3-one 8.6 g of the Schiffs base obtained according to the prescribed method 6a) are dissolved in 100 mL ethanol and 20 mL THF, combined within 30 min at 10-20 C with 0.7 g sodium borohydride and stirred for one hour. After the addition of 10 mL acetone the mixture is stirred for 30 minutes and then diluted with ethyl acetate and water. The product that crystallises out during acidification with conc. hydrochloric acid is filtered off and washed.
Yield: 7.4 g (80%, hydrochloride); m.p. = 235 C (decomposition).
c) 8- {241,1-dimethy1-2-(2,4,6-trimethylphenyl)-ethylamino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,41oxazin-3-one 7.4 g of the benzyl compound obtained in Step b) are hydrogenated in 125 mL
methanol with the addition of 1 g palladium on charcoal (5%) at ambient temperature and normal pressure. Then the catalyst is filtered off and the filtrate is evaporated down. The product that crystallises out on the addition of acetone is suction filtered and washed with acetone and diethyl ether. Yield: 5 g (78%, hydrochloride); m.p. = 160 C
(decomposition).
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 5: 6-hydroxy-8- {1-hydroxy-242-(4-hydroxy-pheny1)-1,1-dimethyl-ethylaminol-ethyl} -4H-benzo[1,4]oxazin-3-one OH Me Me 40 OH
a) 8- 12-{1,1-dimethy1-2-(4-hydroxy-pheny1)-ethylamino]-1-hydroxy-ethyl} -6-benzyloxy-4H-benzo[1,4]oxazin-3-one The title compound is prepared from 10 g (6-benzyloxy-4H-benzo[1,4]oxazin-3-one)-glyoxalhydrate and 4.6 g 1,1-dimethy1-2-(4-hydroxy-pheny1)-ethylamine analogously to the procedure laid down for Example la).
Yield: 9.0 g (64%, hydrochloride); m.p. = 255-258 C.
b) 8- {2-[1,1-dimethy1-2-(4-hydroxy-phenyl)-ethylamino]-1-hydroxy-ethyll-6-hydroxy-41-1-benzo[1,4]oxazin-3-one 5.7 g of the coupling product obtained previously are hydrogenated in the presence of 0.6 g palladium on charcoal (5%) in 100 mL methanol. After uptake of the theoretically calculated amount of hydrogen the catalyst is filtered off and the filtrate is freed from solvent. The residue is dissolved in ethanol with heating and then combined with diethyl ether. The product precipitated is suction filtered and recrystallised once from water. Yield:
The present invention relates to the use of the compounds of general formula 1 OH
Me Me HN n ISR 1 R3 OH
wherein the groups R1, R2 and R3 may have the meanings given herein, for preparing a pharmaceutical composition for the treatment of respiratory complaints.
Background to the invention --Betamimetics (13-adrenergic substances) are known from the prior art. For example reference may be made in this respect to the disclosure of US 4,460,581, which proposes betamimetics for the treatment of a range of diseases.
For drug treatment of diseases it is often desirable to prepare medicaments with a longer duration of activity. As a rule, this ensures that the concentration of the active substance in the body needed to achieve the therapeutic effect is guaranteed for a longer period without the need to re-administer the drug at frequent intervals. Moreover, giving an active substance at longer time intervals contributes to the well-being of the patient to a high degree. It is particularly desirable to prepare a pharmaceutical composition which can be used therapeutically by administration once a day (single dose). The use of a drug once a day has the advantage that the patient can become accustomed relatively quickly to regularly taking the drug at certain times of the day.
The aim of the present invention is therefore to provide betamimetics which on the one hand confer a therapeutic benefit in the treatment of respiratory complaints and are also characterised by a longer duration of activity and can thus be used to prepare pharmaceutical compositions with a longer duration of activity. A particular aim of the invention is to prepare betamimetics which, by virtue of their long-lasting effect, can be used to prepare a drug for administration once a day for treating asthma. A
further objective of the invention, apart from those mentioned above, is to prepare new betamimetics which are not only exceptionally potent but are also characterised by a high degree of selectivity with respect to the 13-adrenoceptor.
Detailed description of the invention It has been found that, surprisingly, the above-mentioned problems are solved by compounds of general formula 1.
Accordingly, the present invention relates to the use of one or more, preferably one, compound of general formula 1 OH
Me Me R
wherein denotes 1 or 2, preferably 1;
RI denotes hydrogen, halogen, CI-C4-alkyl or -0-C1-C4-alkyl;
R2 denotes hydrogen, halogen, Ci-C4-alkyl or -0-C1-C4-alkyl;
R3 denotes CI-C4-alkyl, OH, halogen, -0-Ci-C4-alkyl, -0-Ci-C4-alkylene-COOH, -0-Ci-C4-alkylene-00-0-CI-C4-alkyl, with the proviso that if Ri and R2 each denote ortho-methyl, R3 cannot simultaneously be OH, for preparing a pharmaceutical composition for the treatment of respiratory complaints selected from the group comprising obstructive pulmonary diseases of various origins, pulmonary emphysema of various origins, restrictive pulmonary diseases, interstitial pulmonary diseases, cystic fibrosis, bronchitis of various origins, bronchiectasis, ARDS (adult respiratory distress syndrome) and all forms of pulmonary oedema.
Preferably, the compounds of general formula 1 used as specified above are those wherein denotes 1 or 2, preferably 1;
RI denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R2 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R3 denotes Ci-C4-alkyl, OH, fluorine, chlorine, bromine, -0-C1-C4-alkyl, -0-C1-C4-alkylene-COOH, -0-C1-C4-alkylene-00-0-Ci-C4-alkyl, with the proviso that if RI and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
Preferably, the compounds of general formula 1 used as specified above are those wherein denotes 1;
RI denotes hydrogen or Ci-C4-alkyl;
R2 denotes hydrogen or CI-C4-alkyl;
R3 denotes Ci-C4-alkyl, OH, -0-C1-C4-alkyl, -0-C1-C4-alkylene-COOH or -0-C1-C4- alkylene-00-0-Ci-C4-alkyl, with the proviso that if RI and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
Preferably, the compounds of general formula 1 used as specified above are those wherein n denotes 1;
RI denotes hydrogen, methyl or ethyl;
R2 denotes hydrogen, methyl or ethyl;
R3 denotes methyl, ethyl, OH, methoxy, ethoxy, -0-CH2-COOH, -0-CH2-COOmethyl or -0-CH2-COOethyl, with the proviso that if RI and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
Preferably, the compounds of general formula 1 used as specified above are those wherein denotes 1;
RI denotes hydrogen or methyl;
R2 denotes hydrogen or methyl;
R3 denotes methyl, OH, methoxy, -0-CH2-COOH or -0-CH2-COOethyl, with the proviso that if RI and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
Preferably, according to the invention, the compounds of general formula 1 used as specified above are those wherein R3 denotes methoxy, ethoxy, -0-CH2-COOH, -0-CH2-COOmethyl or -0-CH2-COOethyl, and RI, R2 and n may have the meanings given above.
The present invention further relates to the above-mentioned use of compounds of general formula 1 wherein n denotes 1;
RI denotes halogen, Ci-C4-alkyl or -0-C i-C4-alkyl;
R2 denotes halogen, Ci-C4-alkyl or -0-Ci-C4-alkyl;
R3 denotes halogen, CI-C4-alkyl or -0-Ci-C4-alkyl.
The present invention further relates to the above-mentioned use of compounds of general formula 1 wherein denotes 1;
RI denotes fluorine, chlorine, methyl or methoxy;
R2 denotes fluorine, chlorine, methyl or methoxy;
R3 denotes fluorine, chlorine, methyl or methoxy.
According to another preferred aspect of the present invention the compounds of general formula 1 used as specified above are those wherein n denotesl;
RI denotes hydrogen;
R2 denotes hydrogen, fluorine, chlorine or methyl;
R3 denotes methyl, ethyl, iso-propyl, tert.-butyl, OH, fluorine, chlorine, bromine, methoxy, ethoxy, -0-CH2-COOH, -0-CH2-CH2-COOH, -0-CH2-CH2-CH2-COOH, -0-CH2-COOmethyl, -0-CH2-COOethyl, -0-CH2-CH2-COOmethyl, -0-CH2-CH2-COOethyl, -0-CH2-CH2-CH2-COOmethyl or -0-CH2-CH2-CH2-COOethyl.
Particularly preferably, the compounds of general formula! used as specified above are those wherein denotes 1;
R1 denotes hydrogen;
R2 denotes hydrogen, fluorine, chlorine or methyl;
R3 denotes OH, fluorine, chlorine, methyl, methoxy, ethoxy or -0-CH2-COOH.
Moreover it is particularly preferable according to the invention if the compounds of general formula 1 according to the invention used as specified above are those wherein denotes 1;
RI denotes hydrogen;
R2 denotes halogen, CI-C4-alkyl or -0-C1-C4-alkyl, preferably fluorine, chlorine, methoxy or methyl;
R3 denotes halogen, CI-C4-alkyl or -0-C1-C4-alkyl, preferably fluorine, chlorine, methoxy or methyl.
In another preferred aspect of the present invention the compounds of general formula 1 according to the invention used as specified above are those wherein n = 1 , RI and R2 denote hydrogen and the group R3 may have the meanings given above.
In another preferred aspect of the present invention the compounds of general formula 1 according to the invention used as specified above are those wherein RI and R2 denote hydrogen;
R3 denotes methyl, ethyl, iso-propyl, tert.-butyl, OH, fluorine, chlorine, bromine, methoxy, ethoxy, -0-CH2-COOH, -0-CH2-CH2-COOH, -0-CH2-CH2-CH2-COOH, -0-CH2-COOmethyl, -0-CH2-COOethyl, -0-CH2-CH2-COOmethyl, -0-CH2-CH2-COOethyl, -0-CH2-CH2-CH2-COOmethyl, -0-CH2-CH2-CH2-COOethyl.
Particularly preferably the compounds of general formula 1 according to the invention used as specified above are those wherein n denotes 1;
RI and R2 denote hydrogen;
R3 denotes OH, fluorine, chlorine, methoxy, ethoxy,-0-CH2-COOH, preferably OH, fluorine, chlorine, ethoxy or methoxy.
Particularly preferably the compounds of general formula 1 according to the invention used as specified above are those wherein denotes 1;
RI and R2 denote hydrogen;
R3 denote fluorine, chlorine, methoxy or ethoxy.
The present invention further relates to the above-mentioned use of compounds of general formula 1, wherein denotes 1;
Ri denotes hydrogen, halogen, Ci-C4-alkyl or -0-C i-C4-alkyl;
R2 denotes hydrogen, halogen, Ci-C4-alkyl or -0-C1-C4-alkyl;
R3 denotes hydrogen.
Preferably, the compounds of general formula! used as specified above are those wherein n denotes 1;
RI denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R2 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R3 denotes hydrogen.
The present invention further relates to the above-mentioned use of compounds of general formula 1, wherein denotes 1;
RI denotes fluorine, chlorine, methyl or methoxy;
R2 denotes fluorine, chlorine, methyl or methoxy;
R3 denotes hydrogen.
In the compounds of formula! the groups RI and R2, if they do not represent hydrogen, may each be arranged in the ortho or meta position relative to the bond to the benzylic "-CH2" group. If none of the groups RI and R2 denotes hydrogen, preferred compounds of formula! for the use according to the invention are those wherein either both groups RI
and R2 are ortho or both groups RI and R2 are in the meta configuration, while compounds in which both groups RI and R2 are in the ortho-configuration are of particular importance.
In the compounds of formula! wherein one of the groups RI and R2 does not denote hydrogen, this group may be in the ortho or meta position relative to the bond to the benzylic "-CH2" group. In this case those compounds of formula! wherein the group RI or R2 which does not denote hydrogen is in the ortho configuration are particularly preferred for use according to the invention.
Particularly preferably, one or more of the following compounds of general formula! are used for the purpose described above:
- 6-hydroxy-8-{1-hydroxy-242-(4-methoxy-pheny1)-1,1-dimethyl-ethylaminol-ethyll-4H-benzo[1,4]oxazin-3-one;
- 6-hydroxy-8- {1-hydroxy-2-[2-(4- ethyl-phenoxy-acetate)-1,1-dimethyl-ethylamino]-ethy1}-4H-benzo[1,4]oxazin-3-one;
- 6-hydroxy-8- {1-hydroxy-2-[2-(4-phenoxy-acetic acid)-1,1-dimethyl-ethylamino]-ethy1}-4H-benzo[1,4]oxazin-3-one;
- 8- {2-[1,1-dimethy1-2-(2,4,6-trimethylpheny1)-ethylamino]-1-hydroxy-ethyll-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 6-hydroxy-8- {1-hydroxy-242-(4-hydroxy-pheny1)-1,1-dimethyl-ethylaminoFethyl} -4H-benzo[1,4]oxazin-3-one;
- 6-hydroxy-8- {1-hydroxy-242-(4-isopropyl-pheny1)-1,1dimethyl-ethylamino}-ethyll -4H-benzo[1,4]oxazin-3-one;
- 8- {212-(4-ethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzorl ,4]oxazin-3-one;
- 8- {242-(4-fluoro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo [1,4]oxazin-3-one;
- 8- {212-(4-fluoro-2-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-hydroxy-4H-benzo[1,41oxazin-3-one;
- 8- {242-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(4-ethoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo [1,4]oxazin-3-one;
- 4-(4- {242-hydroxy-2-(6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-ethylamino]-2-methyl-propyll-phenoxy)-butyric acid;
- 8- {24243 ,4-di fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(2-chloro-4-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4]oxazin-3-one;
- 8- {242-(4-chloro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(4-bromo-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(4-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8-1242-(4-fluoro-3-methoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(4-fluoro-2,6-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[l ,4]oxazin-3-one;
- 8- {242-(4-chloro-2-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {212-(4-chloro-3-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-. hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(4-chloro-2-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4] oxazin-3-one;
- 8- {2-[2-(3-chloro-4-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(2,6-difluoro-4-methoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8-1242-(2,5-difluoro-4-methoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo [1,4] oxazin-3-one;
- 8- {242-(4-fluoro-3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(3,5-dichloro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {2-[2-(4-chloro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {2-[2-(3,4,5-trifluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
- 8- {242-(3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one and - 8- (242-(3,4-dichloro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one.
A particularly preferred compound is 6-hydroxy-8-11-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl)-4H-benzo[1,4]oxazin-3-one. The R-enantiomer of the compound is specifically preferred.
In another aspect the present invention relates to the above-mentioned use of the compounds of formula 1 in the form of the individual optical isomers, or mixtures of the individual enantiomers or racemates. It is particularly preferable to use the compounds of formula! for the purpose described above in the form of the enantiomerically pure compounds, while the use of the R-enantiomers of the compounds of formula 1 is of exceptional importance according to the invention.
In another aspect the present invention relates to the above-mentioned use of the compounds of formula! in the form of the acid addition salts with pharmacologically acceptable acids as well as optionally in the form of the solvates and/or hydrates.
The compounds of general formula! are preferably used for preparing a pharmaceutical composition for the treatment of obstructive pulmonary diseases selected from among bronchial asthma, paediatric asthma, severe asthma, acute asthma attacks and chronic bronchitis, while it is particularly preferable according to the invention to use them for preparing a pharmaceutical composition for the treatment of bronchial asthma.
It is also preferable to use the compounds of general formula! for preparing a pharmaceutical composition for the treatment of pulmonary emphysema which has its origins in COPD (chronic obstructive pulmonary disease) or al -proteinase inhibitor deficiency.
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of restrictive pulmonary diseases selected from among allergic alveolitis, restrictive pulmonary diseases triggered by work-related noxious substances, such as asbestosis or silicosis, and restriction caused by lung tumours, such as for example lymphangiosis carcinomatosa, bronchoalveolar carcinoma and lymphomas.
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of interstitial pulmonary diseases selected from among pneumonia caused by infections, such as for example infection by viruses, bacteria, fungi, protozoa, helminths or other pathogens, pneumonitis caused by various factors, such as for example aspiration and left heart insufficiency, radiation-induced pneumonitis or fibrosis, collagenoses, such as for example lupus erythematodes, systemic sclerodermy or sarcoidosis, granulomatoses, such as for example Boeck's disease, idiopathic interstitial pneumonia or idiopathic pulmonary fibrosis (IPF).
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of cystic fibrosis or mucoviscidosis.
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of bronchitis, such as for example bronchitis caused by bacterial or viral infection, allergic bronchitis and toxic bronchitis.
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of bronchiectasis.
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of ARDS (adult respiratory distress syndrome).
It is also preferable to use the compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of pulmonary oedema, for example toxic pulmonary oedema after aspiration or inhalation of toxic substances and foreign substances.
It is particularly preferable to use the compounds detailed above for preparing a pharmaceutical composition for the treatment of asthma or COPD. Also of particular importance is the above-mentioned use of compounds of formula 1 for preparing a pharmaceutical composition for once-a-day treatment of inflammatory and obstructive respiratory complaints, particularly for the once-a-day treatment of asthma.
The present invention also relates to a process for the treatment of the above-mentioned diseases, characterised in that one or more of the above-mentioned compounds of general formula 1 are administered in therapeutically effective amounts. The present invention further relates to processes for the treatment of Asthma, characterised in that one or more of the above-mentioned compounds of general formula 1 are administered once a day in therapeutically effective amounts.
By acid addition salts with pharmacologically acceptable acids are meant for example salts selected from the group comprising the hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate, preferably the hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate.
Of the above-mentioned acid addition salts, the salts of hydrochloric acid, methanesulphonic acid, benzoic acid and acetic acid are particularly preferred according to the invention.
For use according to the invention the compounds of general formula! may optionally be used in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates. If the compounds are used in enantiomerically pure form, the R-enantiomers are preferably used.
Unless otherwise stated, the alkyl groups are straight-chained or branched alkyl groups having Ito 4 carbon atoms. The following are mentioned by way of example:
methyl, ethyl, propyl or butyl. In some cases the abbreviations Me, Et, Prop or Bu are used to denote the groups methyl, ethyl, propyl or butyl. Unless otherwise stated, the definitions propyl and butyl include all the possible isomeric forms of the groups in question. Thus, for example, propyl includes n-propyl and iso-propyl, butyl includes iso-butyl, sec.butyl and tert.-butyl, etc.
Unless otherwise stated, the alkylene groups are branched and unbranched double-bonded alkyl bridges having 1 to 4 carbon atoms. The following are mentioned by way of example: methylene, ethylene, n-propylene or n-butylene.
Unless otherwise stated, the term alkyloxy groups (or -0-alkyl groups) denotes branched and unbranched alkyl groups having 1 to 4 carbon atoms which are linked via an oxygen atom. Examples of these include: methyloxy, ethyloxy, propyloxy or butyloxy.
The abbreviations Me0-, Et0-, Prop0- or BuO- are used in some cases to denote the groups methyloxy, ethyloxy, propyloxy or butyloxy. Unless otherwise stated, the definitions propyloxy and butyloxy include all possible isomeric forms of the groups in question.
Thus, for example, propyloxy includes n-propyloxy and iso-propyloxy, butyloxy includes iso-butyloxy, sec.butyloxy and tert.-butyloxy, etc. In some cases, within the scope of the present invention, the term alkoxy is used instead of the term alkyloxy.
Accordingly, the terms methoxy, ethoxy, propoxy or butoxy may also be used to denote the groups methyloxy, ethyloxy, propyloxy or butyloxy.
halogen within the scope of the present invention denotes fluorine, chlorine, bromine or iodine. Unless stated otherwise, fluorine, chlorine and bromine are the preferred halogens.
The compounds according to the invention may be prepared analogously to methods already known from the prior art. Suitable methods of preparation are known for example from US 4460581, to the entire contents of which reference is made at this point.
The examples of synthesis described below serve to illustrate new compounds according to the invention in more detail. However, they are intended only as examples of procedures to illustrate the invention without restricting it to the subject matter described in an exemplifying capacity hereinafter.
Example 1: 6-hydroxy-8- 1L1-hydroxy-242-(4-methoxy-pheny1)-1,1-dimethyl-ethylamino1-ethyll-4H-benzo[1,4]oxazin-3-one o OH
HN
Me Me OMe OH
a) 8-{241,1-dimethy1-2-(4-methoxy-pheny1)-ethylamino}-1-hydroxy-ethyll-6-benzyloxy-4H-benzo[1,4]oxazin-3-one 7.5 g (6-benzyloxy-4H-benzo[1,4]oxazin-3-one)-glyoxalhydrate are added at 70 C
to a solution of 3.6 g 1,1-dimethy1-2-(4-methoxypheny1)-ethylamine in 100 mL
ethanol and the mixture is stirred for 15 minutes. Then within 30 minutes at 10 to 20 C 1 g sodium borohydride is added. The mixture is stirred for one hour, combined with 10 mL
acetone and stirred for a further 30 minutes. The reaction mixture is diluted with 150 mL ethyl acetate, washed with water, dried with sodium sulphate and evaporated down.
The residue is dissolved in 50 mL methanol and 100 mL ethyl acetate and acidified with conc.
hydrochloric acid. After the addition of 100 mL diethyl ether the product is precipitated out. The crystals are filtered off, washed and recrystallised from 50 mL
ethanol.
Yield: 7 g (68%; hydrochloride); m.p. = 232-234 C.
b) 8- {241,1-dimethy1-2-(4-methoxy-pheny1)-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one 6.8 g of the benzyl compound obtained previously are hydrogenated in 125 mL
methanol with the addition of 1 g palladium on charcoal (5%) at ambient temperature and normal pressure. The catalyst is filtered off and the filtrate is freed from solvent.
After recrystallisation of the residue from 50 mL acetone and some water a solid is obtained which is filtered off and washed.
Yield: 5.0 g (89 %; hydrochloride); m.p. = 155-160 C.
The (R)- and (S)-enantiomers of Example 1 may be obtained from the racemate, for example, by means of chiral HPLC (e.g. column: Chirobiotic T, 250 x 22.1 mm supplied by Messrs Astec). The mobile phase used may be methanol with 0.05 %
triethylamine and 0.05% acetic acid. Silica gel with a particle size of 5 p,m, to which the glycoprotein teicoplanin is covalently bound, may be used as column material.
Retention time (R-enantiomer) = 40.1 min, retention time (S-enantiomer) = 45.9 min. The two enantiomers are obtained by this method in the form of the free bases.
Of outstanding importance according to the invention is the R-enantiomer of Example 1.
Example 2: 6-h_ydroxy-8-{1-hydroxy-242-( ethyl 4-phenoxy-acetate)-1,1-dimethyl-ethylaminoi-ethyll-4H-benzo[1,4]oxazin-3-one HN OH
OH Me Me 1. 0- y 0 ,OEthyl a) 8- {211,1-dimethy1-24 ethyl 4-phenoxy-acetate)-ethylamino]-1-hydroxy-ethy11-benzyloxy-4H-benzo[1,4]oxazin-3-one Analogously to the method described in Example la) the title compound is obtained from g (6-benzyloxy-4H-benzo[1,4]oxazin-3-one)-glyoxalhydrate and 11.8 g 1,1-dimethy1-2-( ethyl 4-phenoxy-acetate)-ethylamine hydrochloride.
15 Yield: 16.5 g (69%, hydrochloride); m.p. = 212-214 C.
b) 8- {2-11,1-dimethy1-2-(4-phenoxy-acetate ethyl)-ethylamino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,4Joxazin-3-one 8 g of the benzylalcohol obtained previously are dissolved in 100 mL ethanol, 100 mL
methanol and 10 mL water and hydrogenated in the presence of 1 g palladium on charcoal (5%). After uptake of the theoretical amount of hydrogen calculated the catalyst is filtered off and the filtrate is evaporated down. The product that crystallises out when the solvent is distilled off is suction filtered and washed.
Yield: 5.5 g (81%; hydrochloride); m.p. = 137-140 C.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
, Example 3: 6-hydroxy-8- { I -hydroxy-2-[2-(4-phenoxy-acetic acid)-1,1-dimethyl-ethylaminoFethyl } -4H-benzo[1,4]oxazin-3-one C)0 OH H
HN I. N
Me Me 11101 0-.COOH
OH
11 g 8-{2-[1,1-dimethy1-2-(4-phenoxy-acetate ethyl)-ethylamino]-1-hydroxy-ethyl} -6-benzyloxy-4H-benzo[1,4]oxazin-3-one hydrochloride (Example 4a) are dissolved in 125 mL methanol and hydrogenated in the presence of 1 g palladium on charcoal (5%). After uptake of the theoretically calculated amount of hydrogen the catalyst is filtered off 2.6 g sodium hydroxide dissolved in 20 mL water are added to the filtrate. The mixture is refluxed for 30 minutes, the methanol is distilled off and the residue is combined with 10 mL water, 20 mL n-butanol and 3.9 mL acetic acid. The precipitated solid is suction filtered and washed with diethyl ether.
Yield: 7 g (87%). The hydrochloride is obtained by recrystallisation from 0.5 molar hydrochloric acid. M.p. = 152 C.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 4: 8- {2-11,1-dimethy1-2-(2,4,6-trimethylpheny1)-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one C)0 OH H Me Me Me 0 Me Me OH
a) 1-(6-benzyloxy-4H-benzo[1,4]oxazin-3-one)-211,1-dimethy1-2-(2,4,6-trimethylpheny1)-ethyliminoi-ethanone 7.2 g (6-benzyloxy-4H-benzo[1,4]oxazin-3-one)-glyoxalhydrate and 3.6 g 1,1-dimethy1-2-(2,4,6-trimethylpheny1)-ethylamine are heated to 70 C for one hour in 100 mL
ethanol.
, WO 2005/102350 CA 02559700 2006-09-After cooling the solid precipitated is filtered off and washed with ethanol and diethyl ether. Yield: 8.6 g (94%); m.p. = 175 C.
b) 8- {2-[1,1-dimethy1-2-(2,4,6-trimethylpheny1)-ethylamino]-1-hydroxy-ethyll-benzylox_y-4H-benzo[1,4]oxazin-3-one 8.6 g of the Schiffs base obtained according to the prescribed method 6a) are dissolved in 100 mL ethanol and 20 mL THF, combined within 30 min at 10-20 C with 0.7 g sodium borohydride and stirred for one hour. After the addition of 10 mL acetone the mixture is stirred for 30 minutes and then diluted with ethyl acetate and water. The product that crystallises out during acidification with conc. hydrochloric acid is filtered off and washed.
Yield: 7.4 g (80%, hydrochloride); m.p. = 235 C (decomposition).
c) 8- {241,1-dimethy1-2-(2,4,6-trimethylphenyl)-ethylamino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,41oxazin-3-one 7.4 g of the benzyl compound obtained in Step b) are hydrogenated in 125 mL
methanol with the addition of 1 g palladium on charcoal (5%) at ambient temperature and normal pressure. Then the catalyst is filtered off and the filtrate is evaporated down. The product that crystallises out on the addition of acetone is suction filtered and washed with acetone and diethyl ether. Yield: 5 g (78%, hydrochloride); m.p. = 160 C
(decomposition).
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 5: 6-hydroxy-8- {1-hydroxy-242-(4-hydroxy-pheny1)-1,1-dimethyl-ethylaminol-ethyl} -4H-benzo[1,4]oxazin-3-one OH Me Me 40 OH
a) 8- 12-{1,1-dimethy1-2-(4-hydroxy-pheny1)-ethylamino]-1-hydroxy-ethyl} -6-benzyloxy-4H-benzo[1,4]oxazin-3-one The title compound is prepared from 10 g (6-benzyloxy-4H-benzo[1,4]oxazin-3-one)-glyoxalhydrate and 4.6 g 1,1-dimethy1-2-(4-hydroxy-pheny1)-ethylamine analogously to the procedure laid down for Example la).
Yield: 9.0 g (64%, hydrochloride); m.p. = 255-258 C.
b) 8- {2-[1,1-dimethy1-2-(4-hydroxy-phenyl)-ethylamino]-1-hydroxy-ethyll-6-hydroxy-41-1-benzo[1,4]oxazin-3-one 5.7 g of the coupling product obtained previously are hydrogenated in the presence of 0.6 g palladium on charcoal (5%) in 100 mL methanol. After uptake of the theoretically calculated amount of hydrogen the catalyst is filtered off and the filtrate is freed from solvent. The residue is dissolved in ethanol with heating and then combined with diethyl ether. The product precipitated is suction filtered and recrystallised once from water. Yield:
3.6 g (72%, hydrochloride); m.p. = 159-162 C.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 6: 6-hydroxy-8- {1-hydroxy-2-1-2-(4-isopropyl-pheny1)-1,1dimeth_yl-ethylaminoi-ethyl } -4H-benzo [1,4] oxazin-3 -one 0.........---,.
H
HN I. N
OH
a) 1-(4-isopropyl-pheny1)-2-methyl-propan-2-ol The reaction of a Grignard compound, prepared from 20 g (119 mmol) 4-isopropylbenzyl chloride, with 11.4 ml (155 mmol) acetone yields the target compound as a colourless oil. Yield: 13.0 g (57%); mass spectrometry: [M+F1J+ = 193.
b) N-[2-(4-isopropyl-phenyl)-1,1-dimethyl-ethyl]Hacetamide A Ritter reaction is carried out with 10.2 g (53 mmol) 1-(4-isopropyl-pheny1)-2-methyl-propan-2-ol in the manner described for Example 7b). The reaction mixture is poured onto ice water and made alkaline with sodium hydroxide solution, during which time a solid is precipitated. This is suction filtered and dried.
Yield: 9.90 g (80%); mass spectrometry: [M+1-1]+ = 234.
c) 2-(4-isopropyl-phenyl)-1,1-dimethyl-ethylamine Reaction of 9.80 g (42 mmol) N42-(4-isopropyl-pheny1)-1,1-dimethyl-ethyll-acetamide analogously to the procedure laid down for Example 7c).
Yield: 7.00 g (71%, hydrochloride); m.p. = 202-206 C.
d) 6-benzyloxy-8-{1-hydroxy-242-(4-isopropyl-pheny1)-1,1-dimethyl-ethylaminol-ethy1}-4H-benzo[1,4]oxazin-3-one 2.18 g (6.1 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 1.1 g (5.8 mmol) 2-(4-isopropyl-phenyl)-1,1-dimethyl-ethylamine are stirred for one hour at 50-80 C in 40 mL ethanol. After cooling to ambient temperature 0.24 g (6.3 mmol) sodium borohydride are added. The mixture is stirred for one hour, diluted with 5 mL
acetone and stirred for a further 30 minutes. The reaction mixture is acidified with hydrochloric acid, combined with 100 mL water and 80 mL ethyl acetate and made alkaline with ammonia. The organic phase is separated off, dried with sodium sulphate and freed from the solvent. The residue is dissolved in 20 mL ethyl acetate and 10 mL water, acidified with conc. hydrochloric acid and diluted with diethyl ether. After the addition of a crystallisation aid the precipitated solid is suction filtered and washed.
White solid.
Yield: 1.7 g (52 %, hydrochloride); m.p. = 220-222 C.
e) 6-hydroxy-8- {1-hydroxy-242-(4-isopropyl-pheny1)-1,1dimethyl-ethylaminol-ethy11-4H-benzoil,4]oxazin-3-one 1.6 g (3.0 mmol) 6-benzyloxy-8-11-hydroxy-242-(4-isopropyl-pheny1)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one are dissolved in methanol and hydrogenated with palladium on charcoal as catalyst at normal pressure and ambient temperature. The catalyst is suction filtered, the solvent distilled off and the residue recrystallised from isopropanol. White solid.
Yield: 1.1 g (85%, hydrochloride); m.p. = 248-250 C; mass spectrometry: [M+1-11- = 399.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 7: 8- {242-(4-ethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-hydroxy-4H-benzo[1,4]oxazin-3-one HN
OH
a) 1-(4-ethyl-pheny1)-2-methyl-propan-2-ol 14.8 g (90 mmol) 1-(4-ethyl-phenyl)-propan-2-one, dissolved in diethyl ether, are added dropwise to 39 mL of a 3 molar solution of methylmagnesium bromide in diethyl ether, while being cooled with the ice bath, in such a way that the temperature does not exceed 30 C. After the addition has ended the reaction mixture is left to reflux for 1.5 hours and then hydrolysed with 10% ammonium chloride solution. After separation of the organic phase the aqueous phase is extracted with diethyl ether. The combined ether phases are washed with water, dried with sodium sulphate and evaporated down. The oil thus obtained is further reacted directly.
Yield: 15.5 g(90%).
b) N42-(4-ethyl-pheny1)-1,1-dimethyl-ethyl]-acetamide 6.2 mL conc. sulphuric acid are added dropwise within 15 minutes to 15.5 g (87 mmol) 1-(4-ethyl-pheny1)-2-methyl-propan-2-ol in 4.8 mL (91 mmol) acetonitrile and 15 mL glacial acetic acid, while the temperature rises to 65 C. Then the mixture is stirred for one hour, diluted with ice water and made alkaline with conc. sodium hydroxide solution . After further stirring for 30 minutes the precipitated solid is suction filtered and washed with water. The crude product is dissolved in ethyl acetate, dried with sodium sulphate and evaporated down. The oil remaining is combined with petroleum ether, during which time a solid is precipitated, which is filtered off and dried.
Yield: 16.3 g (85%); m.p. = 90-92 C.
c) 2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamine 16.3 g (74 mmol) N-[2-(4-ethyl-phenyl)-1,1-dimethyl-ethyll-acetamide and 8.0 g potassium hydroxide are heated for 15 hours in 60 mL ethyleneglycol at reflux temperature. The reaction mixture is combined with ice water and extracted three times with diethyl ether. The combined organic phases are washed with water, dried with sodium sulphate and freed from the solvent. In order to prepare the hydrochloride the crude product is dissolved in acetonitrile and combined successively with ethereal hydrochloric acid and diethyl ether. The precipitated solid is suction filtered and dried.
Yield: 11.0 g (69%, hydrochloride); m.p. = 165-167 C.
d) 6-benzyloxy-8- {242-(4-ethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -4H-benzo[1,4Joxazin-3-one The target compound is prepared analogously to the procedure laid down for Example 6d) from 2.14 g (6.0 mmol) 6-benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 1.0 g (5.6 mmol) 2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamine. White solid.
Yield: 1.7 g (54%, hydrochloride); m.p. 210-214 C.
e) 8- {2-[2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one The hydrogenolysis of 1.45 g (2.75 mmol) 6-benzyloxy-8-{2-[2-(4-ethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll-4H-benzo[1,4]oxazin-3-one according to the prescribed method for Example 6e) yields the target compound in the form of a white solid.
Yield: 1.07 g (92%; hydrochloride); m.p. = 266-269 C; mass spectrometry:
[M+Hi+ = 385.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 8: 8- {242-(4-Fluoro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl -6-hydroxy-4H-benzo[1,4]oxazin-3-one O OH
HN
OH
a) 1-fluoro-2-methy1-442-methyl-propeny1)-benzene 100 mL of a 0.5 molar solution of 4-fluoro-3-methyl-phenylmagnesium bromide in THF
are combined within 30 minutes with 4.7 mL (50 mmol) isopropylaldehyde, while the temperature rises to 45 C . It is stirred for 30 minutes, refluxed for 1 hour and then hydrolysed with 10% ammonium chloride solution. After separation of the organic phase the mixture is extracted with diethyl ether. The organic phases are combined, dried and evaporated down. The alcohol thus obtained is dissolved in 100 mL toluene, combined with 1 g of p-toluenesulphonic acid monohydrate and refluxed for three hours using the water separator. The reaction mixture is poured onto water and made alkaline with conc.
sodium hydroxide solution . After separation of the organic phase this is washed with water, dried with sodium sulphate and freed from the solvent. Fractionated distillation of the residue yields the product in the form of a colourless liquid (b.p. 80-85 C/10 mbar).
Yield: 4.1 g(50%).
b) N42-(4-fluoro-3-methyl-pheny1)-1,1-dimethyl-ethyli-formamide 4.9 mL conc. sulphuric acid are added dropwise at 5-15 C to 1.5 g (31 mmol) sodium cyanide in 5 mL glacial acetic acid. Then the mixture is combined with 3.9 g (24 mmol) 1-fluoro-2-methy1-4-(2-methyl-propeny1)-benzene, dissolved in 10 mL glacial acetic acid, and stirred for 1 hour at 50-60 C. The reaction mixture is diluted with ice water , made alkaline with conc. sodium hydroxide solution and extracted with dichloromethane . The organic phase is dried with sodium sulphate and freed from the solvent in vacuo. The light yellow oil thus obtained is further reacted directly. Yield: 4.3 g (87%).
c) 2(4-fluoro-3-methyl-pheny1)-1,l-dimethyl-ethylamine 4.3 g (20.6 mmol) N-[2-(4-fluoro-3-methyl-phenyl)-1,1-dimethyl-ethyl]-formamide, 20 mL conc. hydrochloric acid and 20 mL water are refluxed for 2 hours. The reaction mixture is diluted with water, made alkaline with conc. sodium hydroxide solution and extracted with dichloromethane. The organic phases are dried with sodium sulphate and evaporated down. The residue is dissolved in ethyl acetate, combined with ethereal hydrochloric acid and cooled. The precipitated crystals are suction filtered and washed with diethyl ether and dried. White solid.
Yield: 3.9 g (87%, hydrochloride); m.p. ¨196-198 C.
d) 6-benzyloxy-8- {242-(4-fluoro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -4H-benzo[1,4]oxazin-3-one 1.10 g (3.1 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 0.50 g (2.8 mmol) 2-(4-fluoro-3-methyl-phenyl)-1,1-dimethyl-ethylamine are reacted and worked up analogously to the procedure laid down for Example 6d). White solid.
Yield: 0.75 g (47%, hydrochloride); m.p. 228-230 C.
e) 8- {242-(4-Fluoro-3-methyl-pheny1)-1,1-dimethyl-ethylamino1-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,41oxazin-3-one The hydrogenation of 0.70 g (1.4 mmol) 6-benzyloxy-8-{242-(4-fluoro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-4H-benzo[1,4]oxazin-3-one yields the target compound as a white solid.
Yield: 0.50 g (87%, hydrochloride); m.p. = 278-280 C; mass spectroscopy: [M+Hr = 389.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 9: 8- {242-(4-fluoro-2-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo(1,4]oxazin-3-one OH
a) 1-(4-fluoro-2-methyl.phenyl)-2-methyl-propyl acetate 500 mL of a 0.5 molar solution of 4-fluoro-6-methylphenylmagnesium bromide and 23.2 mL (260 mmol) isopropylaldehyde are reacted analogously to Example 8a). After hydrolysis with 10% ammonium chloride solution the aqueous phase is separated off and extracted with diethyl ether. The combined organic phases are dried with sodium sulphate and evaporated down. The alcohol thus obtained is then dissolved in 50 mL
acetic anhydride, combined with 1 mL conc. sulphuric acid and stirred for three hours at reflux temperature. Then the reaction mixture is poured onto water, stirred for a further hour and made alkaline. The mixture is extracted with dichloromethane, the organic phases are dried with sodium sulphate and the solvents are distilled off. Fractional distillation of the residue yields the product in the form of a colourless liquid (b.p. 105-110 C/8 mbar). Yield 29.0 g (52%).
b) N42-(4-fluoro-2-methyl-pheny1)-1,1-dimethyl-ethyl]-formamide 29.0 g (130 mmol) 1-(4-fluoro-2-methyl-pheny1)-2-methyl-propyl acetate are reacted and worked up analogously to the procedure laid down for Example 8b).
Yellow oil. Yield: 27.0 g (99%).
c) 2-(4-fluoro-2-methyl-phenyl)-1,1-dimethyl-ethylamine In order to prepare the amine 27.0 g (130 mmol) N42-(4-fluoro-2-methyl-pheny1)-1,1-dimethyl-ethyl]-formamide are reacted as in the procedure laid down for Example 8c).
White solid. Yield: 15.5 g (55%, hydrochloride); m.p. = 277-280 C.
d) 6-benzyloxy-8-124244-fluoro-2-methyl-pheny1)-1,1-dimethyl-eth_ylamino]-1-hydroxy-ethyll-4H-benzo[1,4]oxazin-3-one Prepared analogously to the procedure laid down for Example 6d) from 0.95 g (2.66 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 0.43 g (2.37 mmol) 2-(4-fluoro-2-methyl-phenyl)-1,1-dimethyl-ethylamine.
Yield: 0.75 g (55%, hydrochloride); m.p. = 233-236 C.
e) 8- {242-(4-fluoro-2-methyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl hydroxy-4H-benzo[1,4]oxazin-3-one The debenzylation of 0.70 g (1.36 mmol) 6-benzyloxy-8-124244-fluoro-2-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-4H-benzo[1,4]oxazin-3-one yields the target compound in the form of a white solid.
Yield: 0.50 g (87%, hydrochloride); m.p. = 278-280 C; mass spectroscopy: [M+I-I]f = 389.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 10: 8- {242-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl 1 -6-hydroxy-4H-benzoj1,4Joxazin-3-one 0,.....õ,,..õ
H
le F
OH
a) 1-(2,4-difluoro-pheny1)-2-methyl-propan-2-ol 11.0 mL acetone, diluted with 50 mL diethyl ether, are added dropwise within 20 minutes to a solution of 500 mL 0.25 molar 2,4-difluorobenzylmagnesium bromide in diethyl ether.
Then the mixture is stirred for 1.5 hours at reflux temperature and then hydrolysed with 10% ammonium chloride solution. The ether phase is separated off, washed with water, dried with sodium sulphate and evaporated down. The fractional distillation of the residue yields the alcohol as a colourless liquid (b.p. 70-73 C/ 2 mmbar).
Yield: 20.0 g (86%).
b) N42-(2,4-difluoro-phenyl]-1,1-dimethyl-ethyll-formamide Ritter reaction with 20 g (110 mmol) 1-(2,4-difluoro-phenyl)-2-methyl-propan-2-ol according to the process described for Example 8b). Yellow oil. Yield: 22.0 g (94%).
c) 2-(2,4-difluoro-phenyl)-1,1-dimethyl-ethylamine Reaction of 22.0 g (100 mmol) N-[2-(2,4-difluoro-pheny1]-1,1-dimethyl-ethyl]-formamide analogously to the procedure laid down for Example 8c).
Yield: 16.0 g (72%, hydrochloride); m.p. = 201-203 C.
d) 6-benzyloxy-8- {242-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylaminoi-1-hydroxy-ethyl}-4H-benzo[1,41oxazin-3-one Reaction of 0.89 g (2.49 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acety1)-4H-benzo[1,4]oxazin-3-one and 0.40 g (2.16 mmol) 2-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylamine in the manner described for Example 6d).
Yield: 0.80 g (62%, hydrochloride); m.p. = 245-247 C.
e) 8- {242-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one The hydrogenolysis of 0.70 g (1.35 mmol) 6-benzyloxy-8-{212-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-4H-benzo[1,4]oxazin-3-one yields the target compound as a white solid.
Yield: 0.48 g (83%, hydrochloride); m.p. = 279-280 C; mass spectroscopy:
[M+H]+ = 393.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 11: 8- {242-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one OH
H
HN le N 1 F
OH F
a) 1-(3,5-difluoro-pheny1)-2-methyl-propan-2-ol The target compound is obtained by reacting a Grignard compound, prepared from 25.0 g (121 mmol) 3,5-difluorobenzylbromide, with 12.6 mL (171 mmol) acetone. Yellow oil.
Yield: 13.5 g (60%).
b) 2-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamine The Ritter reaction of 5.5 g (29.5 mmol) 1-(3,5-difluoro-phenyl)-2-methyl-propan-2-ol and 1.8 g sodium cyanide yields 7.0 g formamide, which is treated with hydrochloric acid in order to cleave the formyl group. Light yellow oil. Yield: 4.6 g (75%).
c) 6-benzyloxy-8-{2-[2-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll-4H-benzo[1,4]oxazin-3-one Prepared from 1.73 g (4.84 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acety1)-4H-benzo[1,4]oxazin-3-one and 0.80 g (4.32 mmol) 2-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamine in the usual way.
Yield: 1.50 g (58 %, hydrochloride); m.p. = 240-244 C.
d) 8- {242-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-6-hydroxy-4H-benzo[1,4]oxazin-3-one Hydrogenolysis of 1.30 g (2.43 mmol) 6-benzyloxy-8- {242-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-4H-benzo [1,4] oxazin-3-one yields the target compound as a white solid.
Yield: 0.90 g (86%, hydrochloride); m.p. = 150-158 C; mass spectroscopy: [M+Hr = 393.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 12: 8- {242-(4-ethoxy-phenyl)-1, I -dimethyl-ethylaminol-l-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one 1.1OH o-\
a) benzyl [2-(4-ethoxy-phenyl)-1,1-dimethyl-ethy1]-carbamate 15.0 g (50 mmol) benzyl [2-(4-hydroxy-phenyl)-1,1-dimethyl-ethyl]-carbamate are stirred with 7.5 mL (92 mmol) ethyl iodide and 21 g (150 mmol) potassium carbonate for 10 hours at 90-100 C. The reaction mixture is combined with ethyl acetate, washed twice with water and dried with sodium sulphate. After removal of the solvents by distillation a yellow oil remains (15.0 g, 92%), which is further reacted directly.
b) 2-(4-ethoxy-phenyl)-1,1-dimethyl-ethylamine A solution of 15.0 g (49 mmol) benzyl [2-(4-ethoxy-pheny1)-1,1-dimethyl-ethyl]-carbamate in 100 mL glacial acetic acid is combined with 2 g palladium on charcoal (10%) and then hydrogenated at 5 bar and 40 to 50 C. The catalyst is filtered off and the filtrate is freed from solvent. The residue is dissolved in a little water, made alkaline with conc.
sodium hydroxide solution and extracted with ethyl acetate . The organic phase is washed with water, dried with sodium sulphate and evaporated down. The crude product is dissolved in acetonitrile and acidified with ethereal hydrochloric acid. The solid precipitated after the addition of diethyl ether is suction filtered and dried.
Yield: 8.8 g (hydrochloride, 84%); m.p. = 198-200 C.
c) 6-benzyloxy-8-{242-(4-ethoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-4H-benzo[1,4]oxazin-3-one 2.14 g (6.0 mmol) 6-benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 1.0 g (5.2 mmol) 2-(4-ethoxy-phenyl)-1,1-dimethyl-ethylamine are stirred in 40 mL
ethanol for one hour at 50-80 C. After cooling to ambient temperature 0.23 g (6.0 mmol) sodium borohydride are added and the mixture is stirred for another hour. The reaction mixture is combined with 5 ml acetone, stirred for 30 minutes, acidified with glacial acetic acid and evaporated down. The residue is combined with water and ethyl acetate and made alkaline. The organic phase is separated off, washed with water, dried with sodium sulphate and freed from the solvent in vacuo. The residue is dissolved again in ethyl acetate and water, combined with conc. hydrochloric acid and diluted with diethyl ether.
The precipitated solid is suction filtered and washed with diethyl ether.
White solid.
Yield: 2.0 g (61 %, hydrochloride); m.p. = 214-216 C.
d) 8- {242-(4-ethoxy-pheny1)-1,1-dimethyl-ethyl amino] -1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,41oxazin-3-one 1.5 g (2.8 mmol) 6-benzyloxy-8-{242-(4-ethoxy-pheny1)-1,1-dimethyl-ethylamino]-hydroxy-ethy11-4H-benzo[1,4]oxazin-3-one in 80 mL methanol are hydrogenated with 250 mg palladium on charcoal (10 %) as catalyst at ambient temperature and normal pressure.
The catalyst is suction filtered and the filtrate is evaporated down. The residue is dissolved in 5 mL ethanol by heating, inoculated and diluted with ethyl acetate. The precipitated solid is filtered off and washed. White solid.
Yield 1.0 g (83%, hydrochloride); m.p= 232-235 C; mass spectrometry: [IVI+H]+
= 401.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art .
Example 13: 8-{2-12-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll-6-hydroxy-4H-benzo[1,4]oxazin-3-one HN
OH
a) 1-(3,5-dimethyl-pheny1)-2-methyl-propano1-2-ol Obtained from the reaction of ethyl (3,5-dimethyl-phenyl)-acetate with methylmagnesium bromide.
b) 2-(3,5-dimethyl-phenyl)-1,1-dimethyl-ethylamine By reacting 6.00 g (34 mmol) 1-(3,5-dimethyl-phenyl)-2-methyl-propano1-2-ol and 2.00 g (41 mmol) sodium cyanide in a Ritter reaction 2.40 g 2-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylformamid (35% yield) are obtained. To release the the amine the formamide (2.40 g, 11.7 mmol) is treated with hydrochloric acid. The process and working up take place analogously to the procedure laid down for Example 8c). Oil.
Yield: 1.70 g (82%); mass spectroscopy: [M+1-11+ = 178.
c) 6-benzyloxy-8-{242-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-4H-benzo[1 ,4]oxazin-3-one Prepared analogously to the procedure laid down for Example 8d) from 1.47 g (4.1 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 0.65 g (3.7 mmol) 2-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamine.
Yield: 1.1 g (51%, hydrochloride); m.p. = 220-222 C.
d) 8- t242-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one The target compound was obtained after hydrogenolysis of 0.90 g (1.71 mmol) 6-benzyloxy-8- {21243 ,5-dimethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl -4H-benzo[1,4]oxazin-3-one and recrystallisation of the crude product from isopropanol. White solid.
Yield: 0.50 g (69%, hydrochloride); m.p. = 235-238 C; mass spectroscopy: [M+1-1]+ = 385.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 14: 4-(4- {2-[2-hydroxy-2-(6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-ethylamino]-2-methyl-propyl -phenoxy)-butyric acid a) ethyl 444-(2-amino-2-methyl-propy1)-phenoxyl-butyrate 4.5 g (15.0 mmol) benzyl [2-(4-hydroxy-phenyl)-1,1-dimethyl-ethyl] -carbamate, 2.3 mL
(16.0 mmol) ethyl 4-bromo-butyrate, 2.3 g (16.6 mmol) potassium carbonate and 0.3 g (1.8 mmol) potassium iodide in 20 mL dimethylformamid are heated to 120 C for 13 hours.
The reaction mixture is diluted with ethyl acetate and washed successively with water, sodium hydroxide solution and water. The organic phase is dried with sodium sulphate and evaporated down. The residue is purified by chromatography (eluant:
cyclohexane/ethyl acetate = 9:1). 5.0 g of a yellow oil are isolated, which is dissolved in 50 mL acetic acid and hydrogenated with 1.0 g palladium on charcoal as catalyst at 40 C and 3 bar. The catalyst is filtered off and the filtrate is freed from solvent. The residue is dissolved in diethyl ether and combined with ethereal hydrochloric acid. The precipitated solid is suction filtered and dried.
Yield: 2.9 g (66% over two steps, hydrochloride); m.p. = 103-105 C.
b) 4-(4- {242-(6-benzyloxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-2-hydroxy-ethylamino]-2-methyl-propy1}-phenoxy)-butyrate ethyl 1.20 g (3.36 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 0.90 g (3.22 mmol) ethyl 444-(2-amino-2-methyl-propy1)-phenoxy]-butyrate are reacted in the manner described for Example 8d). The crude product is dissolved in 10 mL
ethyl acetate and 10 mL water and combined with oxalic acid with stirring. The solution is diluted with diethyl ether and the precipitated solid is suction filtered and washed with diethyl ether . Yield: 1.20 g (54%, oxalate); m.p. = 223-227 C.
c) 4-(4-{212-(6-benzyloxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-2-hydroxy-ethylamino]-2-methyl-propyll-phenoxy)-butyric acid A solution of 1.00 g (1.73 mmol) ethyl 4-(4- {242-(6-benzyloxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-2-hydroxy-ethylamino]-2-methyl-propyll-phenoxy)-butyrate in 25 mL methanol is combined with 2.5 mL 1 N sodium hydroxide solution, refluxed for 30 minutes and then neutralised with 1 N hydrochloric acid. The solution is evaporated down and the oil remaining is dissolved in 5 mL n-butanol by heating. After the addition of a crystallisation aid a solid is precipitated, which is suction filtered and washed with acetone and diethyl ether. Yield: 0.75 g (79%); m.p. = 216-218 C.
d) 4-(4- {2-12-hydroxy-2-(6-hydroxy-3-oxo-3,4-dihydro-2H-benzol1,4]oxazin-8-y1)-ethylamino]-2-methyl-propyll-phenoxy)-butyric acid 0.70 g (1.28 mmol) 4-(4-1242-(6-benzyloxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-2-hydroxy-ethylamino]-2-methyl-propyll-phenoxy)-butyric acid are dissolved in 25 mL methanol and 2 mL acetic acid and hydrogenated in the presence of 150 mg palladium on charcoal (10%) at ambient temperature and normal pressure. The catalyst is filtered off and the filtrate is freed from solvent. The product is obtained by crystallisation from a methanol/acetone mixture.
Yield: 0.40 g (68%); m.p. = 201-204 C; mass spectroscopy: [M+1-1] = 459.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 15: 8- {242-(3,4-difluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydrox_y-ethy11-6-hydroxy-4H-benzo[1,4]oxazin-3-one O OH HN
OH
a) 1-(3,4-difluoro-phenyl)-2-methyl-propan-2-ol From 23.0 g (111 mmol) 3,4-difluorobenzylbromide a Grignard compound is prepared, which is then reacted with 11.6 mL (158 mmol) acetone. Light yellow oil.
Yield: 9.7 g (47%); Rf value: 0.55 (ethyl acetate /petroleum ether = 1:3).
b) N42-(3,4-difluoro-pheny1)-1,1-dimethyl-ethyl]-formamide The target compound is obtained by a Ritter reaction with 4.0 g (21.5 mmol) difluoro-pheny1)-2-methyl-propan-2-ol. Light yellow oil.
Yield: 4.0 g (87%); mass spectrometry: [M+1-1]+ = 214.
c) 2-(3,4-difluoro-pheny1)-1,1-dimethyl-ethylamine 4.00 g (18.5 mmol) N12-(3,4-difluoro-pheny1)-1,1-dimethyl-ethyThformamide are dissolved in ethanol, combined with conc. hydrochloric acid and heated overnight at reflux temperature. The reaction solution is poured onto ice water, made alkaline with sodium hydroxide and extracted with tert-butylmethylether. The organic phases are washed with water, dried with sodium sulphate and evaporated down. Yellow oil.
Yield: 3.2 g (92%); mass spectrometry: [M+1-1]+ = 186.
d) 8- {24243 ,4-di fluoro-phenyl)-1,1-dimethyl-ethyl amino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,4]oxazin-3-one 357 mg (1 mmol) 6-benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 185 mg (1 mmol) 2-(3,4-difluoro-phenyl)-1,1-dimethyl-ethylamine are stirred for 30 minutes in 5 mL tetrahydrofiiran at ambient temperature. The mixture is cooled to 0 C and under an argon atmosphere 1.5 mL of a 2 molar solution of lithium borohydride in tetrahydrofuran is added dropwise. The mixture is stirred for 30 min at ambient temperature, combined with 10 mL dichloromethane and 3 mL water, stirred for a further hour and then filtered through Extrelut 8. The eluate containing the ethanolamine is freed from the solvent. The residue is dissolved in methanol and hydrogenated with palladium on charcoal (10%) as catalyst at 2.5 bar and ambient temperature. Then the catalyst is separated off and the crude product purified by chromatography. White solid.
Yield: 31 mg (6%, trifluorethyl acetate); mass spectroscopy: [M+f-1]- = 393.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 16: 8- {242-(2-chloro-4-fluoro-pheny1)-1,1-dimeth_yl-ethylaminol-1-hydroxy-ethyl -6-hydroxy-4H-benzo[1,41oxazin-3-one a) 1-(2-chloro-4-fluoro-pheny1)-2-methyl-propan-2-ol OH
Prepared from 20 g (97 mmol) methyl (2-chloro-4-fluoro-phenyl)-acetate and 98 mL of a 3 molar solution of methylmagnesium bromide analogously to the procedure laid down for Example 6a).
b) N-[2-(2-chloro-4-fluoro-phenyl)-1,1-dimethyl-ethyl]-formamide 7.5 g (37 mmol) 1-(2-chloro-4-fluoro-phenyl)-2-methyl-propan-2-ol were reacted and worked up according to the procedure described for Example 8b). The oil thus obtained was chromatographed for further purification on a short silica gel column (petroleum ether/ethyl acetate = 9:1). Oil. Yield 7.4 g (87%); mass spectrometry: [M+FITE
= 230/232.
c) 2-(2-chloro-4-fluoro-phenyl)-1,1-dimethyl-ethylamine Reaction of 7.4 g (32 mmol) N42-(2-chloro-4-fluoro-pheny1)-1,1-dimethyl-ethyl]-formamide as in the procedure laid down for Example 15c) described. Brown oil.
Yield:
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 6: 6-hydroxy-8- {1-hydroxy-2-1-2-(4-isopropyl-pheny1)-1,1dimeth_yl-ethylaminoi-ethyl } -4H-benzo [1,4] oxazin-3 -one 0.........---,.
H
HN I. N
OH
a) 1-(4-isopropyl-pheny1)-2-methyl-propan-2-ol The reaction of a Grignard compound, prepared from 20 g (119 mmol) 4-isopropylbenzyl chloride, with 11.4 ml (155 mmol) acetone yields the target compound as a colourless oil. Yield: 13.0 g (57%); mass spectrometry: [M+F1J+ = 193.
b) N-[2-(4-isopropyl-phenyl)-1,1-dimethyl-ethyl]Hacetamide A Ritter reaction is carried out with 10.2 g (53 mmol) 1-(4-isopropyl-pheny1)-2-methyl-propan-2-ol in the manner described for Example 7b). The reaction mixture is poured onto ice water and made alkaline with sodium hydroxide solution, during which time a solid is precipitated. This is suction filtered and dried.
Yield: 9.90 g (80%); mass spectrometry: [M+1-1]+ = 234.
c) 2-(4-isopropyl-phenyl)-1,1-dimethyl-ethylamine Reaction of 9.80 g (42 mmol) N42-(4-isopropyl-pheny1)-1,1-dimethyl-ethyll-acetamide analogously to the procedure laid down for Example 7c).
Yield: 7.00 g (71%, hydrochloride); m.p. = 202-206 C.
d) 6-benzyloxy-8-{1-hydroxy-242-(4-isopropyl-pheny1)-1,1-dimethyl-ethylaminol-ethy1}-4H-benzo[1,4]oxazin-3-one 2.18 g (6.1 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 1.1 g (5.8 mmol) 2-(4-isopropyl-phenyl)-1,1-dimethyl-ethylamine are stirred for one hour at 50-80 C in 40 mL ethanol. After cooling to ambient temperature 0.24 g (6.3 mmol) sodium borohydride are added. The mixture is stirred for one hour, diluted with 5 mL
acetone and stirred for a further 30 minutes. The reaction mixture is acidified with hydrochloric acid, combined with 100 mL water and 80 mL ethyl acetate and made alkaline with ammonia. The organic phase is separated off, dried with sodium sulphate and freed from the solvent. The residue is dissolved in 20 mL ethyl acetate and 10 mL water, acidified with conc. hydrochloric acid and diluted with diethyl ether. After the addition of a crystallisation aid the precipitated solid is suction filtered and washed.
White solid.
Yield: 1.7 g (52 %, hydrochloride); m.p. = 220-222 C.
e) 6-hydroxy-8- {1-hydroxy-242-(4-isopropyl-pheny1)-1,1dimethyl-ethylaminol-ethy11-4H-benzoil,4]oxazin-3-one 1.6 g (3.0 mmol) 6-benzyloxy-8-11-hydroxy-242-(4-isopropyl-pheny1)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one are dissolved in methanol and hydrogenated with palladium on charcoal as catalyst at normal pressure and ambient temperature. The catalyst is suction filtered, the solvent distilled off and the residue recrystallised from isopropanol. White solid.
Yield: 1.1 g (85%, hydrochloride); m.p. = 248-250 C; mass spectrometry: [M+1-11- = 399.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 7: 8- {242-(4-ethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-hydroxy-4H-benzo[1,4]oxazin-3-one HN
OH
a) 1-(4-ethyl-pheny1)-2-methyl-propan-2-ol 14.8 g (90 mmol) 1-(4-ethyl-phenyl)-propan-2-one, dissolved in diethyl ether, are added dropwise to 39 mL of a 3 molar solution of methylmagnesium bromide in diethyl ether, while being cooled with the ice bath, in such a way that the temperature does not exceed 30 C. After the addition has ended the reaction mixture is left to reflux for 1.5 hours and then hydrolysed with 10% ammonium chloride solution. After separation of the organic phase the aqueous phase is extracted with diethyl ether. The combined ether phases are washed with water, dried with sodium sulphate and evaporated down. The oil thus obtained is further reacted directly.
Yield: 15.5 g(90%).
b) N42-(4-ethyl-pheny1)-1,1-dimethyl-ethyl]-acetamide 6.2 mL conc. sulphuric acid are added dropwise within 15 minutes to 15.5 g (87 mmol) 1-(4-ethyl-pheny1)-2-methyl-propan-2-ol in 4.8 mL (91 mmol) acetonitrile and 15 mL glacial acetic acid, while the temperature rises to 65 C. Then the mixture is stirred for one hour, diluted with ice water and made alkaline with conc. sodium hydroxide solution . After further stirring for 30 minutes the precipitated solid is suction filtered and washed with water. The crude product is dissolved in ethyl acetate, dried with sodium sulphate and evaporated down. The oil remaining is combined with petroleum ether, during which time a solid is precipitated, which is filtered off and dried.
Yield: 16.3 g (85%); m.p. = 90-92 C.
c) 2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamine 16.3 g (74 mmol) N-[2-(4-ethyl-phenyl)-1,1-dimethyl-ethyll-acetamide and 8.0 g potassium hydroxide are heated for 15 hours in 60 mL ethyleneglycol at reflux temperature. The reaction mixture is combined with ice water and extracted three times with diethyl ether. The combined organic phases are washed with water, dried with sodium sulphate and freed from the solvent. In order to prepare the hydrochloride the crude product is dissolved in acetonitrile and combined successively with ethereal hydrochloric acid and diethyl ether. The precipitated solid is suction filtered and dried.
Yield: 11.0 g (69%, hydrochloride); m.p. = 165-167 C.
d) 6-benzyloxy-8- {242-(4-ethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -4H-benzo[1,4Joxazin-3-one The target compound is prepared analogously to the procedure laid down for Example 6d) from 2.14 g (6.0 mmol) 6-benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 1.0 g (5.6 mmol) 2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamine. White solid.
Yield: 1.7 g (54%, hydrochloride); m.p. 210-214 C.
e) 8- {2-[2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one The hydrogenolysis of 1.45 g (2.75 mmol) 6-benzyloxy-8-{2-[2-(4-ethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll-4H-benzo[1,4]oxazin-3-one according to the prescribed method for Example 6e) yields the target compound in the form of a white solid.
Yield: 1.07 g (92%; hydrochloride); m.p. = 266-269 C; mass spectrometry:
[M+Hi+ = 385.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 8: 8- {242-(4-Fluoro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl -6-hydroxy-4H-benzo[1,4]oxazin-3-one O OH
HN
OH
a) 1-fluoro-2-methy1-442-methyl-propeny1)-benzene 100 mL of a 0.5 molar solution of 4-fluoro-3-methyl-phenylmagnesium bromide in THF
are combined within 30 minutes with 4.7 mL (50 mmol) isopropylaldehyde, while the temperature rises to 45 C . It is stirred for 30 minutes, refluxed for 1 hour and then hydrolysed with 10% ammonium chloride solution. After separation of the organic phase the mixture is extracted with diethyl ether. The organic phases are combined, dried and evaporated down. The alcohol thus obtained is dissolved in 100 mL toluene, combined with 1 g of p-toluenesulphonic acid monohydrate and refluxed for three hours using the water separator. The reaction mixture is poured onto water and made alkaline with conc.
sodium hydroxide solution . After separation of the organic phase this is washed with water, dried with sodium sulphate and freed from the solvent. Fractionated distillation of the residue yields the product in the form of a colourless liquid (b.p. 80-85 C/10 mbar).
Yield: 4.1 g(50%).
b) N42-(4-fluoro-3-methyl-pheny1)-1,1-dimethyl-ethyli-formamide 4.9 mL conc. sulphuric acid are added dropwise at 5-15 C to 1.5 g (31 mmol) sodium cyanide in 5 mL glacial acetic acid. Then the mixture is combined with 3.9 g (24 mmol) 1-fluoro-2-methy1-4-(2-methyl-propeny1)-benzene, dissolved in 10 mL glacial acetic acid, and stirred for 1 hour at 50-60 C. The reaction mixture is diluted with ice water , made alkaline with conc. sodium hydroxide solution and extracted with dichloromethane . The organic phase is dried with sodium sulphate and freed from the solvent in vacuo. The light yellow oil thus obtained is further reacted directly. Yield: 4.3 g (87%).
c) 2(4-fluoro-3-methyl-pheny1)-1,l-dimethyl-ethylamine 4.3 g (20.6 mmol) N-[2-(4-fluoro-3-methyl-phenyl)-1,1-dimethyl-ethyl]-formamide, 20 mL conc. hydrochloric acid and 20 mL water are refluxed for 2 hours. The reaction mixture is diluted with water, made alkaline with conc. sodium hydroxide solution and extracted with dichloromethane. The organic phases are dried with sodium sulphate and evaporated down. The residue is dissolved in ethyl acetate, combined with ethereal hydrochloric acid and cooled. The precipitated crystals are suction filtered and washed with diethyl ether and dried. White solid.
Yield: 3.9 g (87%, hydrochloride); m.p. ¨196-198 C.
d) 6-benzyloxy-8- {242-(4-fluoro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -4H-benzo[1,4]oxazin-3-one 1.10 g (3.1 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 0.50 g (2.8 mmol) 2-(4-fluoro-3-methyl-phenyl)-1,1-dimethyl-ethylamine are reacted and worked up analogously to the procedure laid down for Example 6d). White solid.
Yield: 0.75 g (47%, hydrochloride); m.p. 228-230 C.
e) 8- {242-(4-Fluoro-3-methyl-pheny1)-1,1-dimethyl-ethylamino1-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,41oxazin-3-one The hydrogenation of 0.70 g (1.4 mmol) 6-benzyloxy-8-{242-(4-fluoro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-4H-benzo[1,4]oxazin-3-one yields the target compound as a white solid.
Yield: 0.50 g (87%, hydrochloride); m.p. = 278-280 C; mass spectroscopy: [M+Hr = 389.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 9: 8- {242-(4-fluoro-2-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo(1,4]oxazin-3-one OH
a) 1-(4-fluoro-2-methyl.phenyl)-2-methyl-propyl acetate 500 mL of a 0.5 molar solution of 4-fluoro-6-methylphenylmagnesium bromide and 23.2 mL (260 mmol) isopropylaldehyde are reacted analogously to Example 8a). After hydrolysis with 10% ammonium chloride solution the aqueous phase is separated off and extracted with diethyl ether. The combined organic phases are dried with sodium sulphate and evaporated down. The alcohol thus obtained is then dissolved in 50 mL
acetic anhydride, combined with 1 mL conc. sulphuric acid and stirred for three hours at reflux temperature. Then the reaction mixture is poured onto water, stirred for a further hour and made alkaline. The mixture is extracted with dichloromethane, the organic phases are dried with sodium sulphate and the solvents are distilled off. Fractional distillation of the residue yields the product in the form of a colourless liquid (b.p. 105-110 C/8 mbar). Yield 29.0 g (52%).
b) N42-(4-fluoro-2-methyl-pheny1)-1,1-dimethyl-ethyl]-formamide 29.0 g (130 mmol) 1-(4-fluoro-2-methyl-pheny1)-2-methyl-propyl acetate are reacted and worked up analogously to the procedure laid down for Example 8b).
Yellow oil. Yield: 27.0 g (99%).
c) 2-(4-fluoro-2-methyl-phenyl)-1,1-dimethyl-ethylamine In order to prepare the amine 27.0 g (130 mmol) N42-(4-fluoro-2-methyl-pheny1)-1,1-dimethyl-ethyl]-formamide are reacted as in the procedure laid down for Example 8c).
White solid. Yield: 15.5 g (55%, hydrochloride); m.p. = 277-280 C.
d) 6-benzyloxy-8-124244-fluoro-2-methyl-pheny1)-1,1-dimethyl-eth_ylamino]-1-hydroxy-ethyll-4H-benzo[1,4]oxazin-3-one Prepared analogously to the procedure laid down for Example 6d) from 0.95 g (2.66 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 0.43 g (2.37 mmol) 2-(4-fluoro-2-methyl-phenyl)-1,1-dimethyl-ethylamine.
Yield: 0.75 g (55%, hydrochloride); m.p. = 233-236 C.
e) 8- {242-(4-fluoro-2-methyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl hydroxy-4H-benzo[1,4]oxazin-3-one The debenzylation of 0.70 g (1.36 mmol) 6-benzyloxy-8-124244-fluoro-2-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-4H-benzo[1,4]oxazin-3-one yields the target compound in the form of a white solid.
Yield: 0.50 g (87%, hydrochloride); m.p. = 278-280 C; mass spectroscopy: [M+I-I]f = 389.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 10: 8- {242-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl 1 -6-hydroxy-4H-benzoj1,4Joxazin-3-one 0,.....õ,,..õ
H
le F
OH
a) 1-(2,4-difluoro-pheny1)-2-methyl-propan-2-ol 11.0 mL acetone, diluted with 50 mL diethyl ether, are added dropwise within 20 minutes to a solution of 500 mL 0.25 molar 2,4-difluorobenzylmagnesium bromide in diethyl ether.
Then the mixture is stirred for 1.5 hours at reflux temperature and then hydrolysed with 10% ammonium chloride solution. The ether phase is separated off, washed with water, dried with sodium sulphate and evaporated down. The fractional distillation of the residue yields the alcohol as a colourless liquid (b.p. 70-73 C/ 2 mmbar).
Yield: 20.0 g (86%).
b) N42-(2,4-difluoro-phenyl]-1,1-dimethyl-ethyll-formamide Ritter reaction with 20 g (110 mmol) 1-(2,4-difluoro-phenyl)-2-methyl-propan-2-ol according to the process described for Example 8b). Yellow oil. Yield: 22.0 g (94%).
c) 2-(2,4-difluoro-phenyl)-1,1-dimethyl-ethylamine Reaction of 22.0 g (100 mmol) N-[2-(2,4-difluoro-pheny1]-1,1-dimethyl-ethyl]-formamide analogously to the procedure laid down for Example 8c).
Yield: 16.0 g (72%, hydrochloride); m.p. = 201-203 C.
d) 6-benzyloxy-8- {242-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylaminoi-1-hydroxy-ethyl}-4H-benzo[1,41oxazin-3-one Reaction of 0.89 g (2.49 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acety1)-4H-benzo[1,4]oxazin-3-one and 0.40 g (2.16 mmol) 2-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylamine in the manner described for Example 6d).
Yield: 0.80 g (62%, hydrochloride); m.p. = 245-247 C.
e) 8- {242-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one The hydrogenolysis of 0.70 g (1.35 mmol) 6-benzyloxy-8-{212-(2,4-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-4H-benzo[1,4]oxazin-3-one yields the target compound as a white solid.
Yield: 0.48 g (83%, hydrochloride); m.p. = 279-280 C; mass spectroscopy:
[M+H]+ = 393.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 11: 8- {242-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one OH
H
HN le N 1 F
OH F
a) 1-(3,5-difluoro-pheny1)-2-methyl-propan-2-ol The target compound is obtained by reacting a Grignard compound, prepared from 25.0 g (121 mmol) 3,5-difluorobenzylbromide, with 12.6 mL (171 mmol) acetone. Yellow oil.
Yield: 13.5 g (60%).
b) 2-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamine The Ritter reaction of 5.5 g (29.5 mmol) 1-(3,5-difluoro-phenyl)-2-methyl-propan-2-ol and 1.8 g sodium cyanide yields 7.0 g formamide, which is treated with hydrochloric acid in order to cleave the formyl group. Light yellow oil. Yield: 4.6 g (75%).
c) 6-benzyloxy-8-{2-[2-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll-4H-benzo[1,4]oxazin-3-one Prepared from 1.73 g (4.84 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acety1)-4H-benzo[1,4]oxazin-3-one and 0.80 g (4.32 mmol) 2-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamine in the usual way.
Yield: 1.50 g (58 %, hydrochloride); m.p. = 240-244 C.
d) 8- {242-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-6-hydroxy-4H-benzo[1,4]oxazin-3-one Hydrogenolysis of 1.30 g (2.43 mmol) 6-benzyloxy-8- {242-(3,5-difluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-4H-benzo [1,4] oxazin-3-one yields the target compound as a white solid.
Yield: 0.90 g (86%, hydrochloride); m.p. = 150-158 C; mass spectroscopy: [M+Hr = 393.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 12: 8- {242-(4-ethoxy-phenyl)-1, I -dimethyl-ethylaminol-l-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one 1.1OH o-\
a) benzyl [2-(4-ethoxy-phenyl)-1,1-dimethyl-ethy1]-carbamate 15.0 g (50 mmol) benzyl [2-(4-hydroxy-phenyl)-1,1-dimethyl-ethyl]-carbamate are stirred with 7.5 mL (92 mmol) ethyl iodide and 21 g (150 mmol) potassium carbonate for 10 hours at 90-100 C. The reaction mixture is combined with ethyl acetate, washed twice with water and dried with sodium sulphate. After removal of the solvents by distillation a yellow oil remains (15.0 g, 92%), which is further reacted directly.
b) 2-(4-ethoxy-phenyl)-1,1-dimethyl-ethylamine A solution of 15.0 g (49 mmol) benzyl [2-(4-ethoxy-pheny1)-1,1-dimethyl-ethyl]-carbamate in 100 mL glacial acetic acid is combined with 2 g palladium on charcoal (10%) and then hydrogenated at 5 bar and 40 to 50 C. The catalyst is filtered off and the filtrate is freed from solvent. The residue is dissolved in a little water, made alkaline with conc.
sodium hydroxide solution and extracted with ethyl acetate . The organic phase is washed with water, dried with sodium sulphate and evaporated down. The crude product is dissolved in acetonitrile and acidified with ethereal hydrochloric acid. The solid precipitated after the addition of diethyl ether is suction filtered and dried.
Yield: 8.8 g (hydrochloride, 84%); m.p. = 198-200 C.
c) 6-benzyloxy-8-{242-(4-ethoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-4H-benzo[1,4]oxazin-3-one 2.14 g (6.0 mmol) 6-benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 1.0 g (5.2 mmol) 2-(4-ethoxy-phenyl)-1,1-dimethyl-ethylamine are stirred in 40 mL
ethanol for one hour at 50-80 C. After cooling to ambient temperature 0.23 g (6.0 mmol) sodium borohydride are added and the mixture is stirred for another hour. The reaction mixture is combined with 5 ml acetone, stirred for 30 minutes, acidified with glacial acetic acid and evaporated down. The residue is combined with water and ethyl acetate and made alkaline. The organic phase is separated off, washed with water, dried with sodium sulphate and freed from the solvent in vacuo. The residue is dissolved again in ethyl acetate and water, combined with conc. hydrochloric acid and diluted with diethyl ether.
The precipitated solid is suction filtered and washed with diethyl ether.
White solid.
Yield: 2.0 g (61 %, hydrochloride); m.p. = 214-216 C.
d) 8- {242-(4-ethoxy-pheny1)-1,1-dimethyl-ethyl amino] -1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,41oxazin-3-one 1.5 g (2.8 mmol) 6-benzyloxy-8-{242-(4-ethoxy-pheny1)-1,1-dimethyl-ethylamino]-hydroxy-ethy11-4H-benzo[1,4]oxazin-3-one in 80 mL methanol are hydrogenated with 250 mg palladium on charcoal (10 %) as catalyst at ambient temperature and normal pressure.
The catalyst is suction filtered and the filtrate is evaporated down. The residue is dissolved in 5 mL ethanol by heating, inoculated and diluted with ethyl acetate. The precipitated solid is filtered off and washed. White solid.
Yield 1.0 g (83%, hydrochloride); m.p= 232-235 C; mass spectrometry: [IVI+H]+
= 401.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art .
Example 13: 8-{2-12-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll-6-hydroxy-4H-benzo[1,4]oxazin-3-one HN
OH
a) 1-(3,5-dimethyl-pheny1)-2-methyl-propano1-2-ol Obtained from the reaction of ethyl (3,5-dimethyl-phenyl)-acetate with methylmagnesium bromide.
b) 2-(3,5-dimethyl-phenyl)-1,1-dimethyl-ethylamine By reacting 6.00 g (34 mmol) 1-(3,5-dimethyl-phenyl)-2-methyl-propano1-2-ol and 2.00 g (41 mmol) sodium cyanide in a Ritter reaction 2.40 g 2-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylformamid (35% yield) are obtained. To release the the amine the formamide (2.40 g, 11.7 mmol) is treated with hydrochloric acid. The process and working up take place analogously to the procedure laid down for Example 8c). Oil.
Yield: 1.70 g (82%); mass spectroscopy: [M+1-11+ = 178.
c) 6-benzyloxy-8-{242-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-4H-benzo[1 ,4]oxazin-3-one Prepared analogously to the procedure laid down for Example 8d) from 1.47 g (4.1 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 0.65 g (3.7 mmol) 2-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamine.
Yield: 1.1 g (51%, hydrochloride); m.p. = 220-222 C.
d) 8- t242-(3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one The target compound was obtained after hydrogenolysis of 0.90 g (1.71 mmol) 6-benzyloxy-8- {21243 ,5-dimethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl -4H-benzo[1,4]oxazin-3-one and recrystallisation of the crude product from isopropanol. White solid.
Yield: 0.50 g (69%, hydrochloride); m.p. = 235-238 C; mass spectroscopy: [M+1-1]+ = 385.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 14: 4-(4- {2-[2-hydroxy-2-(6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-ethylamino]-2-methyl-propyl -phenoxy)-butyric acid a) ethyl 444-(2-amino-2-methyl-propy1)-phenoxyl-butyrate 4.5 g (15.0 mmol) benzyl [2-(4-hydroxy-phenyl)-1,1-dimethyl-ethyl] -carbamate, 2.3 mL
(16.0 mmol) ethyl 4-bromo-butyrate, 2.3 g (16.6 mmol) potassium carbonate and 0.3 g (1.8 mmol) potassium iodide in 20 mL dimethylformamid are heated to 120 C for 13 hours.
The reaction mixture is diluted with ethyl acetate and washed successively with water, sodium hydroxide solution and water. The organic phase is dried with sodium sulphate and evaporated down. The residue is purified by chromatography (eluant:
cyclohexane/ethyl acetate = 9:1). 5.0 g of a yellow oil are isolated, which is dissolved in 50 mL acetic acid and hydrogenated with 1.0 g palladium on charcoal as catalyst at 40 C and 3 bar. The catalyst is filtered off and the filtrate is freed from solvent. The residue is dissolved in diethyl ether and combined with ethereal hydrochloric acid. The precipitated solid is suction filtered and dried.
Yield: 2.9 g (66% over two steps, hydrochloride); m.p. = 103-105 C.
b) 4-(4- {242-(6-benzyloxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-2-hydroxy-ethylamino]-2-methyl-propy1}-phenoxy)-butyrate ethyl 1.20 g (3.36 mmol) benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 0.90 g (3.22 mmol) ethyl 444-(2-amino-2-methyl-propy1)-phenoxy]-butyrate are reacted in the manner described for Example 8d). The crude product is dissolved in 10 mL
ethyl acetate and 10 mL water and combined with oxalic acid with stirring. The solution is diluted with diethyl ether and the precipitated solid is suction filtered and washed with diethyl ether . Yield: 1.20 g (54%, oxalate); m.p. = 223-227 C.
c) 4-(4-{212-(6-benzyloxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-2-hydroxy-ethylamino]-2-methyl-propyll-phenoxy)-butyric acid A solution of 1.00 g (1.73 mmol) ethyl 4-(4- {242-(6-benzyloxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-2-hydroxy-ethylamino]-2-methyl-propyll-phenoxy)-butyrate in 25 mL methanol is combined with 2.5 mL 1 N sodium hydroxide solution, refluxed for 30 minutes and then neutralised with 1 N hydrochloric acid. The solution is evaporated down and the oil remaining is dissolved in 5 mL n-butanol by heating. After the addition of a crystallisation aid a solid is precipitated, which is suction filtered and washed with acetone and diethyl ether. Yield: 0.75 g (79%); m.p. = 216-218 C.
d) 4-(4- {2-12-hydroxy-2-(6-hydroxy-3-oxo-3,4-dihydro-2H-benzol1,4]oxazin-8-y1)-ethylamino]-2-methyl-propyll-phenoxy)-butyric acid 0.70 g (1.28 mmol) 4-(4-1242-(6-benzyloxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-y1)-2-hydroxy-ethylamino]-2-methyl-propyll-phenoxy)-butyric acid are dissolved in 25 mL methanol and 2 mL acetic acid and hydrogenated in the presence of 150 mg palladium on charcoal (10%) at ambient temperature and normal pressure. The catalyst is filtered off and the filtrate is freed from solvent. The product is obtained by crystallisation from a methanol/acetone mixture.
Yield: 0.40 g (68%); m.p. = 201-204 C; mass spectroscopy: [M+1-1] = 459.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 15: 8- {242-(3,4-difluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydrox_y-ethy11-6-hydroxy-4H-benzo[1,4]oxazin-3-one O OH HN
OH
a) 1-(3,4-difluoro-phenyl)-2-methyl-propan-2-ol From 23.0 g (111 mmol) 3,4-difluorobenzylbromide a Grignard compound is prepared, which is then reacted with 11.6 mL (158 mmol) acetone. Light yellow oil.
Yield: 9.7 g (47%); Rf value: 0.55 (ethyl acetate /petroleum ether = 1:3).
b) N42-(3,4-difluoro-pheny1)-1,1-dimethyl-ethyl]-formamide The target compound is obtained by a Ritter reaction with 4.0 g (21.5 mmol) difluoro-pheny1)-2-methyl-propan-2-ol. Light yellow oil.
Yield: 4.0 g (87%); mass spectrometry: [M+1-1]+ = 214.
c) 2-(3,4-difluoro-pheny1)-1,1-dimethyl-ethylamine 4.00 g (18.5 mmol) N12-(3,4-difluoro-pheny1)-1,1-dimethyl-ethyThformamide are dissolved in ethanol, combined with conc. hydrochloric acid and heated overnight at reflux temperature. The reaction solution is poured onto ice water, made alkaline with sodium hydroxide and extracted with tert-butylmethylether. The organic phases are washed with water, dried with sodium sulphate and evaporated down. Yellow oil.
Yield: 3.2 g (92%); mass spectrometry: [M+1-1]+ = 186.
d) 8- {24243 ,4-di fluoro-phenyl)-1,1-dimethyl-ethyl amino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,4]oxazin-3-one 357 mg (1 mmol) 6-benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 185 mg (1 mmol) 2-(3,4-difluoro-phenyl)-1,1-dimethyl-ethylamine are stirred for 30 minutes in 5 mL tetrahydrofiiran at ambient temperature. The mixture is cooled to 0 C and under an argon atmosphere 1.5 mL of a 2 molar solution of lithium borohydride in tetrahydrofuran is added dropwise. The mixture is stirred for 30 min at ambient temperature, combined with 10 mL dichloromethane and 3 mL water, stirred for a further hour and then filtered through Extrelut 8. The eluate containing the ethanolamine is freed from the solvent. The residue is dissolved in methanol and hydrogenated with palladium on charcoal (10%) as catalyst at 2.5 bar and ambient temperature. Then the catalyst is separated off and the crude product purified by chromatography. White solid.
Yield: 31 mg (6%, trifluorethyl acetate); mass spectroscopy: [M+f-1]- = 393.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 16: 8- {242-(2-chloro-4-fluoro-pheny1)-1,1-dimeth_yl-ethylaminol-1-hydroxy-ethyl -6-hydroxy-4H-benzo[1,41oxazin-3-one a) 1-(2-chloro-4-fluoro-pheny1)-2-methyl-propan-2-ol OH
Prepared from 20 g (97 mmol) methyl (2-chloro-4-fluoro-phenyl)-acetate and 98 mL of a 3 molar solution of methylmagnesium bromide analogously to the procedure laid down for Example 6a).
b) N-[2-(2-chloro-4-fluoro-phenyl)-1,1-dimethyl-ethyl]-formamide 7.5 g (37 mmol) 1-(2-chloro-4-fluoro-phenyl)-2-methyl-propan-2-ol were reacted and worked up according to the procedure described for Example 8b). The oil thus obtained was chromatographed for further purification on a short silica gel column (petroleum ether/ethyl acetate = 9:1). Oil. Yield 7.4 g (87%); mass spectrometry: [M+FITE
= 230/232.
c) 2-(2-chloro-4-fluoro-phenyl)-1,1-dimethyl-ethylamine Reaction of 7.4 g (32 mmol) N42-(2-chloro-4-fluoro-pheny1)-1,1-dimethyl-ethyl]-formamide as in the procedure laid down for Example 15c) described. Brown oil.
Yield:
5.14 g (79%); mass spectrometry: [M+Hr = 202/204.
d) 8- {2-[2-(2-chloro-4-fluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one 357 mg (1 mmol) 6-benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 202 mg (1 mmol) 2-(2-chloro-4-fluoro-phenyl)-1,1-dimethyl-ethylamine are reacted with lithium borohydride analogously to the procedure laid down for Example 8d). For debenzylation of the ethanolamine thus obtained the latter is dissolved in 3 mL
dichloromethane and cooled to -78 C. At this temperature 2 ml of a 1 molar solution of boron tribromide in dichloromethane is added dropwise and the mixture is allowed to come slowly up to ambient temperature. The reaction mixture is combined with 10 mL
dichloromethane and 3 mL water and filtered through Extrelut . The eluate is freed from the solvent and the residue is purified by chromatography. White solid. Yield:
70 mg (13%, trifluorethyl acetate); mass spectroscopy: [M+II]+ = 409/11.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 17: 8- {242-(4-ch1oro-phenyl)-1,1-dimethyl-ethylaminol-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one OH
HN ii CI
OH
A solution of 300 mg (0.91 mmol) 6-benzyloxy-8-(2,2-dihydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 200 mg (1.09 mmol) 2-(4-chloro-pheny1)-1,1-dimethyl-ethylamine in 3 mL ethanol was combined with molecular sieve and stirred for 90 minutes at 80 C. The mixture was left to cool to ambient temperature, 35 mg (0.91 mmol) sodium borohydride were added and the mixture was stirred for 1 hour. Then the reaction mixture was combined with sodium hydrogen carbonate solution and extracted with ethyl acetate.
The combined organic phases were freed from the solvent and the residue was chromatographed (eluant: hexane/ethyl acetate /methanol), producing 305 mg ethanolamine. This was dissolved in 3 mL dichloromethane and cooled to -78 C
under an argon atmosphere. 3 mL of a 1 molar solution of boron tribromide in dichloromethane were added dropwise and the mixture was left for one hour at -78 C and 20 minutes at ambient temperature with stirring. Then at -78 C 3 mL conc. ammonia solution was added dropwise and the mixture was stirred for 5 minutes. The reaction mixture was combined with ammonium chloride solution and extracted with ethyl acetate. The combined organic phases were evaporated down and the residue was chromatographed for further purification (silica gel; eluant: dichloromethane/methanol + 1% ammonia).
Beige solid: 93 mg (26%); mass spectrometry: [M+H]+ = 391.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 18: 8-{242-(4-bromo-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-hydroxy-4H-benzo[l,4]oxazin-3-one OH Br The preparation of the ethanolamine and debenzylation were carried out as described for Example 17 from 300 mg (0.91 mmol) 6-benzyloxy-8-(2,2-dihydroxy-acety1)-4H-benzo[1,4]oxazin-3-one and 250 mg (1.09) mmol) 2-(4-bromo-pheny1)-1,1-dimethyl-ethylamine. Beige solid. Yield: 54 mg (14%); mass spectrometry: [M+H]+ = 435, 437.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 19: 8- {242-(4-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,4]oxazin-3-one OH
300 mg (0.91 mmol) 6-benzyloxy-8-(2,2-dihydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 183 mg (1.09 mmol) 2-(4-fluoro-phenyl)-1,1-dimethyl-ethylamine were dissolved in 3 ml ethanol. Molecular sieve was added and the mixture was heated to 80 C for minutes. After cooling to ambient temperature, 35 mg (0.91 mmol) sodium borohydride were added. The mixture was stirred for 1 hour at ambient temperature, then sodium hydrogen carbonate solution was added to the reaction mixture and it was extracted with ethyl acetate. The organic phases were evaporated down and the residue was chromatographed (eluant: hexane/ethyl acetate /methanol). The ethanolamine thus obtained (223 mg) was dissolved in methanol in order to cleave the benzyl protecting group and hydrogenated with 150 mg palladium hydroxide as catalyst at ambient temperature and normal pressure. The catalyst was separated off by filtration through Celite , the filtrate was freed from solvent and the residue was chromatographed (silica gel;
eluant:
dichloromethane/methanol). Beige solid.
Yield: 76 mg (22%); mass spectrometry: [M+H]+ = 375.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
The following compounds of formula! according to the invention may also be obtained analogously to the Examples of synthesis described above:
Example 20: 8- {242-(4-fluoro-3-methoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 21: 8- {242-(4-fluoro-2,6-dimethyl-pheny1)-1,1-dimethyl-ethylaminoll -hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 22: 8-1242-(4-chloro-2-methyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo [1,4]oxazin-3 -one;
Example 23: 8- {2-[2-(4-chloro-3-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 24: 8-1242-(4-chloro-2-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,41oxazin-3-one;
Example 25: 8- {2-[2-(3-chloro-4-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 26: 8- {242-(2,6-difluoro-4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 27: 8- {242-(2,5-difluoro-4-methoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 28: 8- {242-(4-fluoro-3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl1-6-hydroxy-4H-benzo[1,41oxazin-3-one;
Example 29: 8- {242-(3,5-dichloro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 30: 8- {212-(4-chloro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4]oxazin-3-one;
Example 31: 8- {21243,4,546 fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 32: 8-1242-(3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 33: 8-1242-(3,4-dichloro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one.
Suitable preparations for administering the compounds of formula 1 include for example tablets, capsules, suppositories, solutions, powders, etc. The content of the pharmaceutically active compound(s) should be in the range from 0.05 to 90 wt.-%, preferably 0.1 to 50 wt.-% of the composition as a whole. Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Syrups or elixirs containing the active substances or combinations of active substances according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
Solutions are prepared in the usual way, e.g. with the addition of isotonic agents, preservatives such as p-hydroxybenzoates or stabilisers such as alkali metal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers and/or dispersants, while if water is used as diluent, for example, organic solvents may optionally be used as solubilisers or dissolving aids, and the solutions may be transferred into injection vials or ampoules or infusion bottles.
Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose), emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).
For oral use the tablets may obviously contain, in addition to the carriers specified, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additional substances such as starch, preferably potato starch, gelatine and the like.
Lubricants such as magnesium stearate, sodium laurylsulphate and talc may also be used to produce the tablets. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the abovementioned excipients.
In the preferred use of the compounds of formula 1 for the treatment of asthma or COPD
according to the invention it is particularly preferred to use preparations or pharmaceutical formulations which are suitable for inhalation. Inhalable preparations include inhalable powders, propellant-containing metered-dose aerosols or propellant-free inhalable solutions. Within the scope of the present invention, the term propellant-free inhalable solutions also includes concentrates or sterile ready-to-use inhalable solutions. The formulations which may be used within the scope of the present invention are described in more detail in the next part of the specification.
The inhalable powders which may be used according to the invention may contain! either on its own or in admixture with suitable physiologically acceptable excipients.
If the active substances 1 are present in admixture with physiologically acceptable excipients, the following physiologically acceptable excipients may be used to prepare these inhalable powders according to the invention: monosaccharides (e.g.
glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextrans), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g.
sodium chloride, calcium carbonate) or mixtures of these excipients. Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
Within the scope of the inhalable powders according to the invention the excipients have a maximum average particle size of up to 250 pm, preferably between 10 and 150 pm, most preferably between 15 and 80 pm. In some cases it may seem appropriate to add finer excipient fractions with an average particle size of 1 to 9 1.tm to the excipients mentioned above. These finer excipients are also selected from the group of possible excipients listed hereinbefore. Finally, in order to prepare the inhalable powders according to the invention, micronised active substance 1, preferably with an average particle size of 0.5 to 10 gam, more preferably from 1 to 5 i.tm, is added to the excipient mixture. Processes for producing the inhalable powders according to the invention by grinding and micronising and lastly mixing the ingredients together are known from the prior art.
The inhalable powders according to the invention may be administered using inhalers known from the prior art.
The inhalation aerosols containing propellant gas according to the invention may contain the compounds 1 dissolved in the propellant gas or in dispersed form. The compounds 1 may be contained in separate formulations or in a common formulation, in which the compounds 1 are either both dissolved, both dispersed or in each case only one component is dissolved and the other is dispersed.
The propellant gases which may be used to prepare the inhalation aerosols are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The above-mentioned propellant gases may be used on their own or mixed together. Particularly preferred propellant gases are halogenated alkane derivatives selected from TG134a and TG227 and mixtures thereof.
The propellant-driven inhalation aerosols may also contain other ingredients such as co-solvents, stabilisers, surfactants, antioxidants, lubricants and pH
adjusters. All these ingredients are known in the art.
The propellant-driven inhalation aerosols according to the invention mentioned above may be administered using inhalers known in the art (MDIs = metered dose inhalers).
Moreover, the active substances 1 according to the invention may be administered in the form of propellant-free inhalable solutions and suspensions. The solvent used may be an aqueous or alcoholic, preferably an ethanolic solution. The solvent may be water on its own or a mixture of water and ethanol. The relative proportion of ethanol compared with water is not limited but the maximum is preferably up to 70 percent by volume, more particularly up to 60 percent by volume and most preferably up to 30 percent by volume.
The remainder of the volume is made up of water. The solutions or suspensions containing 1 are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. The pH may be adjusted using acids selected from inorganic or organic acids. Examples of particularly suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid. Examples of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc. Preferred inorganic acids are hydrochloric and sulphuric acids. It is also possible to use the acids which have already formed an acid addition salt with one of the active substances. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. If desired, mixtures of the above acids may be used, particularly in the case of acids which have other properties in addition to their acidifying qualities, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example. According to the invention, it is particularly preferred to use hydrochloric acid to adjust the pH.
If desired, the addition of editic acid (EDTA) or one of the known salts thereof, sodium edetate, as stabiliser or complexing agent may be omitted in these formulations. Other embodiments may contain this compound or these compounds. In a preferred embodiment the content based on sodium edetate is less than 100 mg/100m1, preferably less than 50mg/100m1, more preferably less than 20mg/100m1. Generally, inhalable solutions in which the content of sodium edetate is from 0 to 10mg/100m1 are preferred.
Co-solvents and/or other excipients may be added to the propellant-free inhalable solutions. Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols - particularly isopropyl alcohol, glycols - particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters. The terms excipients and additives in this context denote any pharmacologically acceptable substance which is not an active substance but which can be formulated with the active substance or substances in the physiologically suitable solvent in order to improve the qualitative properties of the active substance formulation. Preferably, these substances have no pharmacological effect or, in connection with the desired therapy, no appreciable or at least no undesirable pharmacological effect. The excipients and additives include, for example, surfactants such as soya lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or prolong the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art.
The additives also include pharmacologically acceptable salts such as sodium chloride as isotonic agents.
The preferred excipients include antioxidants such as ascorbic acid, for example, provided that it has not already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins and provitamins occurring in the human body.
Preservatives may be used to protect the formulation from contamination with pathogens.
Suitable preservatives are those which are known in the art, particularly cetyl pyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art. The preservatives mentioned above are preferably present in concentrations of up to 50 mg/100 ml, more preferably between 5 and mg/100 ml.
Preferred formulations contain, in addition to the solvent water and the active substance 1, only benzalkonium chloride and sodium edetate. In another preferred embodiment, no 15 sodium edetate is present.
The dosage of the compounds according to the invention is naturally highly dependent on the method of administration and the complaint which is being treated. When administered by inhalation the compounds of formula 1 are characterised by a high potency even at doses in the lig range. The compounds of formula 1 may also be used effectively above the 20 jig range. The dosage may then be in the gram range, for example.
In another aspect the present invention relates to the above-mentioned pharmaceutical formulations as such, which are characterised in that they contain a compound of formula 1, particularly preferably the above-mentioned pharmaceutical formulations administered by inhalation.
. -The following examples of formulations illustrate the present invention without restricting its scope:
Examples of Pharmaceutical Formulations 5 A) Tablets per tablet active substance of formula 1 100 mg lactose 140 mg maize starch 240 mg polyvinylpyrrolidone 15 mg magnesium stearate 5 mg 500 mg The finely ground active substance, lactose and some of the corn starch are mixed together.
The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.
B) Tablets per tablet active substance of formula 1 80 mg lactose 55 mg maize starch 190 mg microcrystalline cellulose 35 mg polyvinylpyrrolidone 15 mg sodium-carboxymethyl starch 23 mg magnesium stearate 2 mg 400 mg The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened.
The sodium carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
C) Ampoule solution active substance of formula 1 50 mg sodium chloride 50 mg water for inj. 5m1 The active substance is dissolved in water at its own pH or optionally at pH
5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.
D) Metered-dose aerosol active substance of formula 1 0.005 sorbitolan trioleate 0.1 monofluorotrichloromethane and TG134a : TG227 2:1 ad 100 The suspension is transferred into a conventional aerosol container with a metering valve. Preferably, 50 ill of suspension are delivered per spray. The active substance may also be metered in higher doses if desired (e.g. 0.02 % by weight).
E) Solutions (in mg/100m1) active substance 1 333.3 mg benzalkonium chloride 10.0 mg EDTA 50.0 mg HC1 (1n) ad pH 3.4 This solution may be prepared in the usual way.
F) Powder for inhalation active substance of formula 1 12 lag lactose monohydrate ad 25 mg The powder for inhalation is produced in the usual way by mixing the individual ingredients together.
d) 8- {2-[2-(2-chloro-4-fluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one 357 mg (1 mmol) 6-benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 202 mg (1 mmol) 2-(2-chloro-4-fluoro-phenyl)-1,1-dimethyl-ethylamine are reacted with lithium borohydride analogously to the procedure laid down for Example 8d). For debenzylation of the ethanolamine thus obtained the latter is dissolved in 3 mL
dichloromethane and cooled to -78 C. At this temperature 2 ml of a 1 molar solution of boron tribromide in dichloromethane is added dropwise and the mixture is allowed to come slowly up to ambient temperature. The reaction mixture is combined with 10 mL
dichloromethane and 3 mL water and filtered through Extrelut . The eluate is freed from the solvent and the residue is purified by chromatography. White solid. Yield:
70 mg (13%, trifluorethyl acetate); mass spectroscopy: [M+II]+ = 409/11.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 17: 8- {242-(4-ch1oro-phenyl)-1,1-dimethyl-ethylaminol-1-hydroxy-ethyll -6-hydroxy-4H-benzo[1,4]oxazin-3-one OH
HN ii CI
OH
A solution of 300 mg (0.91 mmol) 6-benzyloxy-8-(2,2-dihydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 200 mg (1.09 mmol) 2-(4-chloro-pheny1)-1,1-dimethyl-ethylamine in 3 mL ethanol was combined with molecular sieve and stirred for 90 minutes at 80 C. The mixture was left to cool to ambient temperature, 35 mg (0.91 mmol) sodium borohydride were added and the mixture was stirred for 1 hour. Then the reaction mixture was combined with sodium hydrogen carbonate solution and extracted with ethyl acetate.
The combined organic phases were freed from the solvent and the residue was chromatographed (eluant: hexane/ethyl acetate /methanol), producing 305 mg ethanolamine. This was dissolved in 3 mL dichloromethane and cooled to -78 C
under an argon atmosphere. 3 mL of a 1 molar solution of boron tribromide in dichloromethane were added dropwise and the mixture was left for one hour at -78 C and 20 minutes at ambient temperature with stirring. Then at -78 C 3 mL conc. ammonia solution was added dropwise and the mixture was stirred for 5 minutes. The reaction mixture was combined with ammonium chloride solution and extracted with ethyl acetate. The combined organic phases were evaporated down and the residue was chromatographed for further purification (silica gel; eluant: dichloromethane/methanol + 1% ammonia).
Beige solid: 93 mg (26%); mass spectrometry: [M+H]+ = 391.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 18: 8-{242-(4-bromo-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-hydroxy-4H-benzo[l,4]oxazin-3-one OH Br The preparation of the ethanolamine and debenzylation were carried out as described for Example 17 from 300 mg (0.91 mmol) 6-benzyloxy-8-(2,2-dihydroxy-acety1)-4H-benzo[1,4]oxazin-3-one and 250 mg (1.09) mmol) 2-(4-bromo-pheny1)-1,1-dimethyl-ethylamine. Beige solid. Yield: 54 mg (14%); mass spectrometry: [M+H]+ = 435, 437.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
Example 19: 8- {242-(4-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,4]oxazin-3-one OH
300 mg (0.91 mmol) 6-benzyloxy-8-(2,2-dihydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one and 183 mg (1.09 mmol) 2-(4-fluoro-phenyl)-1,1-dimethyl-ethylamine were dissolved in 3 ml ethanol. Molecular sieve was added and the mixture was heated to 80 C for minutes. After cooling to ambient temperature, 35 mg (0.91 mmol) sodium borohydride were added. The mixture was stirred for 1 hour at ambient temperature, then sodium hydrogen carbonate solution was added to the reaction mixture and it was extracted with ethyl acetate. The organic phases were evaporated down and the residue was chromatographed (eluant: hexane/ethyl acetate /methanol). The ethanolamine thus obtained (223 mg) was dissolved in methanol in order to cleave the benzyl protecting group and hydrogenated with 150 mg palladium hydroxide as catalyst at ambient temperature and normal pressure. The catalyst was separated off by filtration through Celite , the filtrate was freed from solvent and the residue was chromatographed (silica gel;
eluant:
dichloromethane/methanol). Beige solid.
Yield: 76 mg (22%); mass spectrometry: [M+H]+ = 375.
The (R)- and (S)-enantiomers of this embodiment may be obtained by separation of the racemate analogously to common methods known in the art.
The following compounds of formula! according to the invention may also be obtained analogously to the Examples of synthesis described above:
Example 20: 8- {242-(4-fluoro-3-methoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 21: 8- {242-(4-fluoro-2,6-dimethyl-pheny1)-1,1-dimethyl-ethylaminoll -hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 22: 8-1242-(4-chloro-2-methyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo [1,4]oxazin-3 -one;
Example 23: 8- {2-[2-(4-chloro-3-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 24: 8-1242-(4-chloro-2-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy11-6-hydroxy-4H-benzo[1,41oxazin-3-one;
Example 25: 8- {2-[2-(3-chloro-4-fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethy1}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 26: 8- {242-(2,6-difluoro-4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 27: 8- {242-(2,5-difluoro-4-methoxy-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 28: 8- {242-(4-fluoro-3,5-dimethyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl1-6-hydroxy-4H-benzo[1,41oxazin-3-one;
Example 29: 8- {242-(3,5-dichloro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 30: 8- {212-(4-chloro-3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4]oxazin-3-one;
Example 31: 8- {21243,4,546 fluoro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 32: 8-1242-(3-methyl-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyll hydroxy-4H-benzo[1,4]oxazin-3-one;
Example 33: 8-1242-(3,4-dichloro-pheny1)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl } -6-hydroxy-4H-benzo[1,4]oxazin-3-one.
Suitable preparations for administering the compounds of formula 1 include for example tablets, capsules, suppositories, solutions, powders, etc. The content of the pharmaceutically active compound(s) should be in the range from 0.05 to 90 wt.-%, preferably 0.1 to 50 wt.-% of the composition as a whole. Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Syrups or elixirs containing the active substances or combinations of active substances according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
Solutions are prepared in the usual way, e.g. with the addition of isotonic agents, preservatives such as p-hydroxybenzoates or stabilisers such as alkali metal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers and/or dispersants, while if water is used as diluent, for example, organic solvents may optionally be used as solubilisers or dissolving aids, and the solutions may be transferred into injection vials or ampoules or infusion bottles.
Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose), emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).
For oral use the tablets may obviously contain, in addition to the carriers specified, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additional substances such as starch, preferably potato starch, gelatine and the like.
Lubricants such as magnesium stearate, sodium laurylsulphate and talc may also be used to produce the tablets. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the abovementioned excipients.
In the preferred use of the compounds of formula 1 for the treatment of asthma or COPD
according to the invention it is particularly preferred to use preparations or pharmaceutical formulations which are suitable for inhalation. Inhalable preparations include inhalable powders, propellant-containing metered-dose aerosols or propellant-free inhalable solutions. Within the scope of the present invention, the term propellant-free inhalable solutions also includes concentrates or sterile ready-to-use inhalable solutions. The formulations which may be used within the scope of the present invention are described in more detail in the next part of the specification.
The inhalable powders which may be used according to the invention may contain! either on its own or in admixture with suitable physiologically acceptable excipients.
If the active substances 1 are present in admixture with physiologically acceptable excipients, the following physiologically acceptable excipients may be used to prepare these inhalable powders according to the invention: monosaccharides (e.g.
glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextrans), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g.
sodium chloride, calcium carbonate) or mixtures of these excipients. Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
Within the scope of the inhalable powders according to the invention the excipients have a maximum average particle size of up to 250 pm, preferably between 10 and 150 pm, most preferably between 15 and 80 pm. In some cases it may seem appropriate to add finer excipient fractions with an average particle size of 1 to 9 1.tm to the excipients mentioned above. These finer excipients are also selected from the group of possible excipients listed hereinbefore. Finally, in order to prepare the inhalable powders according to the invention, micronised active substance 1, preferably with an average particle size of 0.5 to 10 gam, more preferably from 1 to 5 i.tm, is added to the excipient mixture. Processes for producing the inhalable powders according to the invention by grinding and micronising and lastly mixing the ingredients together are known from the prior art.
The inhalable powders according to the invention may be administered using inhalers known from the prior art.
The inhalation aerosols containing propellant gas according to the invention may contain the compounds 1 dissolved in the propellant gas or in dispersed form. The compounds 1 may be contained in separate formulations or in a common formulation, in which the compounds 1 are either both dissolved, both dispersed or in each case only one component is dissolved and the other is dispersed.
The propellant gases which may be used to prepare the inhalation aerosols are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The above-mentioned propellant gases may be used on their own or mixed together. Particularly preferred propellant gases are halogenated alkane derivatives selected from TG134a and TG227 and mixtures thereof.
The propellant-driven inhalation aerosols may also contain other ingredients such as co-solvents, stabilisers, surfactants, antioxidants, lubricants and pH
adjusters. All these ingredients are known in the art.
The propellant-driven inhalation aerosols according to the invention mentioned above may be administered using inhalers known in the art (MDIs = metered dose inhalers).
Moreover, the active substances 1 according to the invention may be administered in the form of propellant-free inhalable solutions and suspensions. The solvent used may be an aqueous or alcoholic, preferably an ethanolic solution. The solvent may be water on its own or a mixture of water and ethanol. The relative proportion of ethanol compared with water is not limited but the maximum is preferably up to 70 percent by volume, more particularly up to 60 percent by volume and most preferably up to 30 percent by volume.
The remainder of the volume is made up of water. The solutions or suspensions containing 1 are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. The pH may be adjusted using acids selected from inorganic or organic acids. Examples of particularly suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid. Examples of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc. Preferred inorganic acids are hydrochloric and sulphuric acids. It is also possible to use the acids which have already formed an acid addition salt with one of the active substances. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. If desired, mixtures of the above acids may be used, particularly in the case of acids which have other properties in addition to their acidifying qualities, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example. According to the invention, it is particularly preferred to use hydrochloric acid to adjust the pH.
If desired, the addition of editic acid (EDTA) or one of the known salts thereof, sodium edetate, as stabiliser or complexing agent may be omitted in these formulations. Other embodiments may contain this compound or these compounds. In a preferred embodiment the content based on sodium edetate is less than 100 mg/100m1, preferably less than 50mg/100m1, more preferably less than 20mg/100m1. Generally, inhalable solutions in which the content of sodium edetate is from 0 to 10mg/100m1 are preferred.
Co-solvents and/or other excipients may be added to the propellant-free inhalable solutions. Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols - particularly isopropyl alcohol, glycols - particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters. The terms excipients and additives in this context denote any pharmacologically acceptable substance which is not an active substance but which can be formulated with the active substance or substances in the physiologically suitable solvent in order to improve the qualitative properties of the active substance formulation. Preferably, these substances have no pharmacological effect or, in connection with the desired therapy, no appreciable or at least no undesirable pharmacological effect. The excipients and additives include, for example, surfactants such as soya lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or prolong the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art.
The additives also include pharmacologically acceptable salts such as sodium chloride as isotonic agents.
The preferred excipients include antioxidants such as ascorbic acid, for example, provided that it has not already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins and provitamins occurring in the human body.
Preservatives may be used to protect the formulation from contamination with pathogens.
Suitable preservatives are those which are known in the art, particularly cetyl pyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art. The preservatives mentioned above are preferably present in concentrations of up to 50 mg/100 ml, more preferably between 5 and mg/100 ml.
Preferred formulations contain, in addition to the solvent water and the active substance 1, only benzalkonium chloride and sodium edetate. In another preferred embodiment, no 15 sodium edetate is present.
The dosage of the compounds according to the invention is naturally highly dependent on the method of administration and the complaint which is being treated. When administered by inhalation the compounds of formula 1 are characterised by a high potency even at doses in the lig range. The compounds of formula 1 may also be used effectively above the 20 jig range. The dosage may then be in the gram range, for example.
In another aspect the present invention relates to the above-mentioned pharmaceutical formulations as such, which are characterised in that they contain a compound of formula 1, particularly preferably the above-mentioned pharmaceutical formulations administered by inhalation.
. -The following examples of formulations illustrate the present invention without restricting its scope:
Examples of Pharmaceutical Formulations 5 A) Tablets per tablet active substance of formula 1 100 mg lactose 140 mg maize starch 240 mg polyvinylpyrrolidone 15 mg magnesium stearate 5 mg 500 mg The finely ground active substance, lactose and some of the corn starch are mixed together.
The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.
B) Tablets per tablet active substance of formula 1 80 mg lactose 55 mg maize starch 190 mg microcrystalline cellulose 35 mg polyvinylpyrrolidone 15 mg sodium-carboxymethyl starch 23 mg magnesium stearate 2 mg 400 mg The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened.
The sodium carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
C) Ampoule solution active substance of formula 1 50 mg sodium chloride 50 mg water for inj. 5m1 The active substance is dissolved in water at its own pH or optionally at pH
5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.
D) Metered-dose aerosol active substance of formula 1 0.005 sorbitolan trioleate 0.1 monofluorotrichloromethane and TG134a : TG227 2:1 ad 100 The suspension is transferred into a conventional aerosol container with a metering valve. Preferably, 50 ill of suspension are delivered per spray. The active substance may also be metered in higher doses if desired (e.g. 0.02 % by weight).
E) Solutions (in mg/100m1) active substance 1 333.3 mg benzalkonium chloride 10.0 mg EDTA 50.0 mg HC1 (1n) ad pH 3.4 This solution may be prepared in the usual way.
F) Powder for inhalation active substance of formula 1 12 lag lactose monohydrate ad 25 mg The powder for inhalation is produced in the usual way by mixing the individual ingredients together.
Claims (31)
1. Use of a compound of formula 1 or a pharmacologically acceptable acid addition salt thereof, wherein n denotes 1;
R1 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R2 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R3 denotes C1-C4-alkyl, OH, halogen, -O-C1-C4-alkyl, -O-C1-C4-alkylene-COOH, -O-C1-C4-alkylene-CO-O-C1-C4-alkyl, with the proviso that if R1 and R2 each denote ortho-methyl, R3 cannot simultaneously be OH, for the treatment of a respiratory complaint selected from the group consisting of obstructive pulmonary diseases of various origins, pulmonary emphysema of various origins, restrictive pulmonary diseases, interstitial pulmonary diseases, cystic fibrosis, bronchitis of various origins, bronchiectasis, adult respiratory distress syndrome (ARDS) and all forms of pulmonary oedema.
R1 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R2 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R3 denotes C1-C4-alkyl, OH, halogen, -O-C1-C4-alkyl, -O-C1-C4-alkylene-COOH, -O-C1-C4-alkylene-CO-O-C1-C4-alkyl, with the proviso that if R1 and R2 each denote ortho-methyl, R3 cannot simultaneously be OH, for the treatment of a respiratory complaint selected from the group consisting of obstructive pulmonary diseases of various origins, pulmonary emphysema of various origins, restrictive pulmonary diseases, interstitial pulmonary diseases, cystic fibrosis, bronchitis of various origins, bronchiectasis, adult respiratory distress syndrome (ARDS) and all forms of pulmonary oedema.
2. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 1, wherein n denotes 1;
R1 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R2 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R3 denotes C1-C4-alkyl, OH, fluorine, chlorine, bromine, -O-C1-C4-alkyl, -O-C1-a4-alkylene-COOH, -O-C1-C4-alkylene-CO-O-C1-C4-alkyl, with the proviso that if R1 and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
R1 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R2 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R3 denotes C1-C4-alkyl, OH, fluorine, chlorine, bromine, -O-C1-C4-alkyl, -O-C1-a4-alkylene-COOH, -O-C1-C4-alkylene-CO-O-C1-C4-alkyl, with the proviso that if R1 and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
3. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 1, wherein n denotes 1;
R1 denotes hydrogen or C1-C4-alkyl;
R2 denotes hydrogen or C1-C4-alkyl;
R3 denotes C1-C4-alkyl, OH, -O-C1-C4-alkyl, -O-C1-C4-alkylene-COOH
or -O-C1-C4-alkylene-CO-O-C1-C4-alkyl, with the proviso that if R1 and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
R1 denotes hydrogen or C1-C4-alkyl;
R2 denotes hydrogen or C1-C4-alkyl;
R3 denotes C1-C4-alkyl, OH, -O-C1-C4-alkyl, -O-C1-C4-alkylene-COOH
or -O-C1-C4-alkylene-CO-O-C1-C4-alkyl, with the proviso that if R1 and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
4. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 1, wherein n denotes 1;
R1 denotes hydrogen, methyl or ethyl;
R2 denotes hydrogen, methyl or ethyl;
R3 denotes methyl, ethyl, OH, methoxy, ethoxy, -O-CH2-COOH, -O-CH2-COOmethyl or -O-CH2-COOethyl, with the proviso that if R1 and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
R1 denotes hydrogen, methyl or ethyl;
R2 denotes hydrogen, methyl or ethyl;
R3 denotes methyl, ethyl, OH, methoxy, ethoxy, -O-CH2-COOH, -O-CH2-COOmethyl or -O-CH2-COOethyl, with the proviso that if R1 and R2 each denote ortho-methyl, R3 cannot simultaneously be OH.
5. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 1, wherein n denotes 1;
R1 denotes halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R2 denotes halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R3 denotes halogen, C1-C4-alkyl or -O-C1-C4-alkyl.
R1 denotes halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R2 denotes halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R3 denotes halogen, C1-C4-alkyl or -O-C1-C4-alkyl.
6. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 5, wherein n denotes 1;
R1 denotes fluorine, chlorine, methyl or methoxy;
R2 denotes fluorine, chlorine, methyl or methoxy;
R3 denotes fluorine, chlorine, methyl or methoxy.
R1 denotes fluorine, chlorine, methyl or methoxy;
R2 denotes fluorine, chlorine, methyl or methoxy;
R3 denotes fluorine, chlorine, methyl or methoxy.
7. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 1, wherein n denotes 1;
R1 denotes hydrogen;
R2 denotes hydrogen, fluorine, chlorine or methyl;
R3 denotes methyl, ethyl, iso-propyl, tert.-butyl, OH, fluorine, chlorine, bromine, methoxy, ethoxy, -O-CH2-COOH, -O-CH2-CH2-COOH, -O-CH2-CH2-CH2-COOH, -O-CH2-COOmethyl, -O-CH2-COOethyl, -O-CH2-CH2-COOmethyl, -O-CH2-CH2-COOethyl, -O-CH2-CH2-CH2-COOmethyl, -O-CH2-CH2-CH2-COOethyl.
R1 denotes hydrogen;
R2 denotes hydrogen, fluorine, chlorine or methyl;
R3 denotes methyl, ethyl, iso-propyl, tert.-butyl, OH, fluorine, chlorine, bromine, methoxy, ethoxy, -O-CH2-COOH, -O-CH2-CH2-COOH, -O-CH2-CH2-CH2-COOH, -O-CH2-COOmethyl, -O-CH2-COOethyl, -O-CH2-CH2-COOmethyl, -O-CH2-CH2-COOethyl, -O-CH2-CH2-CH2-COOmethyl, -O-CH2-CH2-CH2-COOethyl.
8. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 7, wherein n denotes 1;
R1 denotes hydrogen;
R2 denotes hydrogen, fluorine, chlorine or methyl;
R3 denotes OH, fluorine, chlorine, methyl, methoxy, ethoxy or -O-CH2-COOH.
R1 denotes hydrogen;
R2 denotes hydrogen, fluorine, chlorine or methyl;
R3 denotes OH, fluorine, chlorine, methyl, methoxy, ethoxy or -O-CH2-COOH.
9. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 1, wherein n denotes 1;
R1 and R2 denote hydrogen;
R3 denotes methyl, ethyl, iso-propyl, tert.-butyl, OH, fluorine, chlorine, bromine, methoxy, ethoxy, -O-CH2-COOH, -O-CH2-CH2-COOH, -O-CH2-CH2-CH2-COOH, -O-CH2-COOmethyl, -O-CH2-COOethyl, -O-CH2-CH2-COOmethyl, -O-CH2-CH2-COOethyl, -O-CH2-CH2-CH2-COOmethyl, -O-CH2-CH2-CH2-COOethyl.
R1 and R2 denote hydrogen;
R3 denotes methyl, ethyl, iso-propyl, tert.-butyl, OH, fluorine, chlorine, bromine, methoxy, ethoxy, -O-CH2-COOH, -O-CH2-CH2-COOH, -O-CH2-CH2-CH2-COOH, -O-CH2-COOmethyl, -O-CH2-COOethyl, -O-CH2-CH2-COOmethyl, -O-CH2-CH2-COOethyl, -O-CH2-CH2-CH2-COOmethyl, -O-CH2-CH2-CH2-COOethyl.
10. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 9, wherein n denotes 1;
R1 and R2 denote hydrogen;
R3 denotes OH, fluorine, chlorine, methoxy, ethoxy, -O-CH2-COOH, preferably OH, fluorine, chlorine, ethoxy or methoxy.
R1 and R2 denote hydrogen;
R3 denotes OH, fluorine, chlorine, methoxy, ethoxy, -O-CH2-COOH, preferably OH, fluorine, chlorine, ethoxy or methoxy.
11. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 4, wherein R3 denotes methoxy, ethoxy, -O-CH2-COOH, -O-CH2-COOmethyl or -O-CH2-COOethyl, and R1, R2 and n have the meanings given in any one of claims 7 to 10.
12. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 1, wherein n denotes 1;
R1 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R2 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R3 denotes hydrogen.
R1 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R2 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl;
R3 denotes hydrogen.
13. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 12, wherein n denotes 1;
R1 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R2 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R3 denotes hydrogen.
R1 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R2 denotes hydrogen, fluorine, chlorine, methyl or methoxy;
R3 denotes hydrogen.
14. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 1, wherein the compound is 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one, or a pharmacologically acceptable acid addition salt thereof.
15. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to claim 14, which is the R-enantiomer thereof.
16. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of an obstructive pulmonary disease selected from among bronchial asthma, paediatric asthma, severe asthma, acute asthma attacks and chronic bronchitis.
17. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 16 for the treatment of bronchial asthma.
18. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of pulmonary emphysema which has its origins in chronic obstructive pulmonary disease (COPD) or al-proteinase inhibitor deficiency.
19. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of a restrictive pulmonary disease selected from among allergic alveolitis, restrictive pulmonary diseases triggered by work-related noxious substances, and restriction caused by lung tumours.
20. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of a restrictive pulmonary disease selected from among asbestosis, silicosis, lymphangiosis carcinomatosa, bronchoalveolar carcinoma and lymphomas.
21. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of an interstitial pulmonary disease selected from among pneumonia caused by infection, pneumonitis caused by aspiration and left heart insufficiency, radiation-induced pneumonitis or fibrosis, collagenoses, and granulomatoses.
22. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of an interstitial pulmonary disease selected from among pneumonia caused by infection by viruses, bacteria, fungi, protozoa and helminths.
23. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of an interstitial pulmonary disease selected from among lupus erythematodes, systemic sclerodermy and sarcoidosis.
24. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of an interstitial pulmonary disease selected from among Boeck's disease, idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis (IPF).
25. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of cystic fibrosis or mucoviscidosis, bronchiectasis or adult respiratory distress syndrome (ARDS).
26. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of bronchitis.
27. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of bronchitis caused by bacterial or viral infection, allergic bronchitis or toxic bronchitis.
28. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of pulmonary oedema.
29. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for the treatment of toxic pulmonary oedema after aspiration or inhalation of a toxic substance or foreign substance.
30. Use of a compound of formula 1, or a pharmacologically acceptable acid addition salt thereof, according to any one of claims 1 to 15 for once-a-day treatment of asthma.
31. A pharmaceutical formulation for use in the treatment of asthma comprising a compound of formula 1 as defined in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, or a pharmacologically acceptable acid addition salt thereof, and a suitable physiologically acceptable excipient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004019539.0 | 2004-04-22 | ||
DE102004019539A DE102004019539A1 (en) | 2004-04-22 | 2004-04-22 | New drugs for the treatment of respiratory diseases |
PCT/EP2005/004075 WO2005102350A1 (en) | 2004-04-22 | 2005-04-18 | Benzoxazine for treating respiratory tract diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2559700A1 CA2559700A1 (en) | 2005-11-03 |
CA2559700C true CA2559700C (en) | 2013-06-11 |
Family
ID=34966948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2559700A Active CA2559700C (en) | 2004-04-22 | 2005-04-18 | Benzoxazine for treating respiratory tract diseases |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1765355B1 (en) |
JP (1) | JP2007533684A (en) |
KR (2) | KR101338947B1 (en) |
CN (1) | CN1946406A (en) |
AU (1) | AU2005235420C1 (en) |
BR (1) | BRPI0510084A (en) |
CA (1) | CA2559700C (en) |
DE (1) | DE102004019539A1 (en) |
DK (1) | DK1765355T3 (en) |
EA (1) | EA012045B1 (en) |
EC (1) | ECSP066948A (en) |
ES (1) | ES2403184T3 (en) |
IL (1) | IL177663A (en) |
NO (1) | NO20065061L (en) |
NZ (1) | NZ551272A (en) |
PL (1) | PL1765355T3 (en) |
SG (1) | SG152233A1 (en) |
UA (1) | UA85707C2 (en) |
WO (1) | WO2005102350A1 (en) |
ZA (1) | ZA200606547B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
DE102004024452A1 (en) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosol formulation for the inhalation of beta agonists |
JP5270343B2 (en) | 2005-08-15 | 2013-08-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Beta mimetic manufacturing method |
BRPI0618370A2 (en) * | 2005-11-09 | 2011-08-30 | Boehringer Ingelheim Int | aerosol drug formulation, drug use and inhalation kit |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
PL2231642T3 (en) | 2008-01-11 | 2014-04-30 | Novartis Ag | Pyrimidines as kinase inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
CA2828219A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Pyrazolo [1,5-a] pyridines as trk inhibitors |
US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
WO2018108669A1 (en) | 2016-12-12 | 2018-06-21 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol |
GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
BR0110331A (en) * | 2000-04-27 | 2003-01-07 | Boehringer Ingelheim Pharma | Beta-mimicking substances that have long-lasting activity, processes for preparing them and their use as medicines |
DE10130371A1 (en) * | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | New drug compositions based on anticholinergics, corticosteroids and betamimetics |
DE10253282A1 (en) * | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration |
-
2004
- 2004-04-22 DE DE102004019539A patent/DE102004019539A1/en not_active Withdrawn
-
2005
- 2005-04-18 WO PCT/EP2005/004075 patent/WO2005102350A1/en active Application Filing
- 2005-04-18 EA EA200601837A patent/EA012045B1/en not_active IP Right Cessation
- 2005-04-18 NZ NZ551272A patent/NZ551272A/en not_active IP Right Cessation
- 2005-04-18 ES ES05740045T patent/ES2403184T3/en active Active
- 2005-04-18 CN CNA200580012623XA patent/CN1946406A/en active Pending
- 2005-04-18 JP JP2007508807A patent/JP2007533684A/en active Pending
- 2005-04-18 AU AU2005235420A patent/AU2005235420C1/en not_active Ceased
- 2005-04-18 KR KR1020067024543A patent/KR101338947B1/en not_active IP Right Cessation
- 2005-04-18 DK DK05740045.9T patent/DK1765355T3/en active
- 2005-04-18 UA UAA200612036A patent/UA85707C2/en unknown
- 2005-04-18 PL PL05740045T patent/PL1765355T3/en unknown
- 2005-04-18 EP EP05740045A patent/EP1765355B1/en active Active
- 2005-04-18 KR KR1020137008584A patent/KR20130042662A/en not_active Application Discontinuation
- 2005-04-18 BR BRPI0510084-4A patent/BRPI0510084A/en not_active IP Right Cessation
- 2005-04-18 CA CA2559700A patent/CA2559700C/en active Active
- 2005-04-18 SG SG200902504-0A patent/SG152233A1/en unknown
-
2006
- 2006-08-07 ZA ZA200606547A patent/ZA200606547B/en unknown
- 2006-08-23 IL IL177663A patent/IL177663A/en not_active IP Right Cessation
- 2006-10-23 EC EC2006006948A patent/ECSP066948A/en unknown
- 2006-11-02 NO NO20065061A patent/NO20065061L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2005235420C1 (en) | 2011-02-24 |
EP1765355A1 (en) | 2007-03-28 |
IL177663A0 (en) | 2006-12-31 |
KR20130042662A (en) | 2013-04-26 |
EA200601837A1 (en) | 2007-04-27 |
KR20070054599A (en) | 2007-05-29 |
SG152233A1 (en) | 2009-05-29 |
ES2403184T3 (en) | 2013-05-16 |
ZA200606547B (en) | 2008-04-30 |
PL1765355T3 (en) | 2013-08-30 |
NO20065061L (en) | 2006-11-07 |
NZ551272A (en) | 2010-10-29 |
DK1765355T3 (en) | 2013-04-08 |
CN1946406A (en) | 2007-04-11 |
AU2005235420B2 (en) | 2010-10-28 |
DE102004019539A1 (en) | 2005-11-10 |
JP2007533684A (en) | 2007-11-22 |
UA85707C2 (en) | 2009-02-25 |
ECSP066948A (en) | 2006-12-20 |
WO2005102350A1 (en) | 2005-11-03 |
EP1765355B1 (en) | 2013-03-06 |
AU2005235420A1 (en) | 2005-11-03 |
KR101338947B1 (en) | 2013-12-10 |
BRPI0510084A (en) | 2007-10-16 |
EA012045B1 (en) | 2009-08-28 |
IL177663A (en) | 2014-04-30 |
CA2559700A1 (en) | 2005-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2559700C (en) | Benzoxazine for treating respiratory tract diseases | |
CA2506082C (en) | Novel medicaments for the treatment of chronic obstructive pulmonary disease | |
US7160882B2 (en) | Long acting β-2-agonists and their use as medicaments | |
US7429583B2 (en) | Betamimetics for the treatment of respiratory complaints | |
JP4916317B2 (en) | Novel sustained acting β-2-agonists and their use as drugs | |
CA2565243A1 (en) | Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases | |
US7307076B2 (en) | Beta agonists for the treatment of respiratory diseases | |
US7423036B2 (en) | Long-acting betamimetics for the treatment of respiratory complaints | |
US20090181961A1 (en) | Novel medicaments for the treatment of respiratory diseases | |
JP2007537185A (en) | Substituted cycloalkyl derivatives, methods for their preparation and their use as drugs | |
US20110053926A1 (en) | New Pharmaceutically-Active Compounds for the Treatment of Respiratory Diseases | |
US7405232B2 (en) | Long acting beta-2 agonists and their use as medicaments | |
US7563806B2 (en) | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | |
MXPA06010577A (en) | Benzoxazine for treating respiratory tract diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |